Medical use of interferon-lambda for treatment of fibrosis
Interferon-lambda proteins provide a novel therapeutic option for treating fibrosis by inhibiting collagen deposition and fibrosis in various organs, addressing the limitations of current treatments.
Patent Information
- Application Number
- JP2024125837
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-12-20
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for fibrotic diseases are limited in efficacy and often associated with significant side effects, failing to halt the self-perpetuating process of fibrosis once established, with no standard treatments approved for various organs beyond idiopathic pulmonary fibrosis.
The use of interferon-lambda (IFN-λ) proteins or functional mimetics, such as pegylated forms, antibodies, or small molecule chemicals, to activate interferon-lambda receptors, thereby inhibiting fibrosis in organs like the kidneys, lungs, intestines, skin, and liver.
Interferon-lambda demonstrates direct antifibrotic effects in vitro and in vivo, reducing collagen deposition and fibrosis markers, offering a novel therapeutic approach with potential for multiple types of fibrosis without the side effects of existing treatments.
Smart Images

Figure 2024156844000008 
Figure 2024156844000009 
Figure 2024156844000010
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for treating fibrosis. The present invention relates to a method for treating fibrosis. It has direct antifibrotic effects both in vitro and in vivo, and multiple types of The present invention provides a novel method for the treatment of fibrosis in humans, which is an effective treatment for the treatment of fibrosis in humans. Disclose new research. [Background technology]
[0002] Fibrotic diseases are an abnormal wound healing response in which excess fibrous connective tissue forms in an organ or tissue. It is a disease characterized by an excess of extracellular matrix (ECM) components (e.g., collagen). The deposition and accumulation of fibronectin and fibronectin leads to pathological remodeling of the organ. This can result in hardening and scarring of the affected tissue, ultimately leading to organ failure.
[0003] Wounds in solid organs generally result in the influx of neutrophils, macrophages, eosinophils and lymphocytes to the wound site. It begins with endothelial injury, platelet aggregation and activation which leads to an inflammatory response accompanied by lymphocyte infiltration. Infiltrating inflammatory cells and affected epithelial cells serve to further amplify this inflammatory response. They secrete a variety of growth factors and cytokines, including TGF-β, PDGF, and IL-13. The molecule activates macrophages, resulting in recruitment, proliferation and activation of fibroblasts at the wound site. Activated fibroblasts or myofibroblasts increase the expression of α-smooth muscle actin. They are characterized by secreting collagen and other ECM components to form a cellular substratum. This stabilizes the epithelium on this temporary matrix. This allows proliferation and migration of endothelial and endothelial cells, regenerating the damaged tissue. The injury process is halted, fibroblasts undergo apoptosis, and the wound response is resolved.
[0004] In fibrotic remodeling, persistent tissue injury or damage or dysregulation of repair pathways results in This leads to an inappropriate wound response. Excessive deposition of collagen and ECM and excessive This leads to excessive cross-linking, resulting in the accumulation of excess ECM beyond the normal requirements. This is associated with persistent myofibroblast activation, damage to epithelial cells, and loss of normal tissue architecture. do.
[0005] Fibrotic diseases can affect any organ or tissue (e.g., kidney, lung, intestine, skin, or liver). The cause of fibrotic diseases may depend on the organ or tissue involved. Other types of interstitial lung disease include idiopathic pulmonary fibrosis, which is a rare condition that is characterized by a lack of specificity and is not known. It is recognized that the causes of this disease include exposure to environmental allergens that cause hypersensitivity pneumonitis. Fibrosis and ultimately cirrhosis can occur due to exposure to a variety of factors, including environmental and dietary factors or infectious agents. It is caused by chronic liver damage sustained through exposure to alcohol. A high-fat / carbohydrate diet can also lead to cirrhosis of the liver. High blood pressure, exposure to toxins, and various types of autoimmune diseases can damage the kidneys and cause fibrosis. It can cause remodeling and loss of function. Many types of inflammatory bowel disease (e.g. For example, Crohn's disease or celiac disease are characterized by fibrosis leading to narrowing and / or malabsorption. This may be a cause for modeling.
[0006] Treatment of progressive fibrosis is primarily by treating the underlying disease. For example, blood pressure control of diabetes, improving glucose management in diabetes, or exposure to harmful allergens or environmental However, in many patients, once fibrotic remodeling is established, Once this occurs, the disease becomes self-perpetuating and simple remedial treatment of the underlying disease will not cure this process. Some fibrotic diseases can be treated with anti-inflammatory and immunosuppressive drugs. Although there are treatments available that are effective in only a subset of patients, they do not appear to halt the disease. Rather, it delays it.
[0007] To date, there are only two effective treatments for fibrotic remodeling, both of which are Pirfenidone is approved for use only in idiopathic pulmonary fibrosis (IPF). It was approved for use in the treatment of IPF in Japan in 2008 and in Europe in 2011. It is a small molecule drug that acts in part, but not completely, through downregulation of TGF-β. Nintedanib may act through multiple possible mechanisms of action. Inhibits tyrosine kinase activity in the PDGF receptor, FGF receptor, and Both compounds delay the onset of IPF, but Based on current research, it may only extend lifespan by a maximum of two years. are associated with serious side effects, resulting in over 30% of patients discontinuing their long-term use. Unacceptable. To date, there is no standard treatment approved for the indication of fibrosis. Summary of the Invention
[0008] Thus, there is currently an unmet need for improved treatment of fibrotic diseases in all organs. There exists an unmet medical need. It is therefore an object of the present invention to provide a novel method for treating fibrosis. The purpose is to provide.
[0009] Discovery and initial description of the interferon-lambda (IFN-lambda) family in early 2003 has opened an exciting new chapter in the field of IFN research. IFN-λ1, IFN-λ 2, four distinct but highly related proteins, designated IFN-λ3 and IFN-λ4. These proteins also bind to interleukin-29 (IL-29), ), also known as IL-28A, IL-28B and IFNL4. Four cytokines constitute the type III subset of IFNs. Heterodimeric receptor complexes distinct from the receptors used by type I and type II IFNs. For a number of reasons, including the fact that they signal through fusion, both type I and type II They are different from type I IFN (IFN-a / b) and type III IFN (IFN-1 ) signal through distinct receptor complexes, which are expressed in various target cells. They activate the same intracellular signaling pathways and have many of the same biological activities, including antiviral activity. Consistent with these antiviral activities, the IFN-λ gene and its corresponding transcription factor Expression of the protein can be induced by infection with many types of viruses. The expression and major biological activity of type III IFN (IFN-λ) is very different from that of type I IFN. However, IFN-α is widely expressed on most cell types, including leukocytes. Unlike ceptor, the IFN-λ receptor is primarily restricted to cells of epithelial origin. The potential clinical importance of IFN-λ as a novel antiviral therapeutic agent is already evident. In addition, preclinical studies by several groups have demonstrated that IFN-λ inhibits certain types of These results suggest that the compound may also be useful as a potential therapeutic agent for cancer.
[0010] In the present invention, the inventors have demonstrated that cytokines of the interferon-lambda family are have direct-acting antifibrotic effects both in vitro and in vivo, and The proteins are being used to design effective new treatments for multiple types of fibrosis. We disclose novel research that demonstrates for the first time that it is possible to In particular embodiments, for example, the following items are provided: (Item 1) Interferon-lambda for use in the treatment of fibrosis. (Item 2) 2. The interferon-lambda according to item 1, wherein the interferon-lambda is IFN-lambda 1, IFN-lambda 2, IFN-lambda 3 or IFN-lambda 4 or a functional mimetic thereof. (Item 3) 3. The interferon-lambda according to item 2, wherein the functional mimetic is a fragment, variant or derivative of IFN-λ1, IFN-λ2, IFN-λ3 or IFN-λ4. (Item 4) 4. The interferon-lambda of item 3, wherein the functional mimetic is pegylated. (Item 5) The interferon-lambda according to item 4, wherein the functional mimetic is peg-interferon lambda-1a. (Item 6) The interferon-lambda according to item 2, wherein the functional mimetic is an antibody. (Item 7) The interferon-lambda of item 2, wherein the functional mimetic is a small molecule chemical. (Item 8) 8. Interferon-lambda according to any one of items 1 to 7, wherein said interferon-lambda or functional mimetic activates the interferon-lambda receptor. (Item 9) 9. The interferon-lambda of any one of items 1 to 8, wherein the fibrosis is renal fibrosis. (Item 10) 9. The interferon-lambda of any one of items 1 to 8, wherein the fibrosis is pulmonary fibrosis. (Item 11) 9. The interferon-lambda of any one of items 1 to 8, wherein the fibrosis is small intestinal fibrosis. (Item 12) 9. The interferon-lambda of any one of items 1 to 8, wherein the fibrosis is dermal fibrosis. (Item 13) 9. The interferon-lambda of any one of items 1 to 8, wherein the fibrosis is liver fibrosis. (Item 14) Use of interferon-lambda for the preparation of a medicament for the treatment of fibrosis. (Item 15) 15. Use of interferon-lambda according to item 14, wherein the interferon-lambda is IFN-lambda1, IFN-lambda2, IFN-lambda3 or IFN-lambda4 or a functional mimetic thereof. (Item 16) 16. Use of interferon-lambda according to item 15, wherein the functional mimetic is a fragment, variant or derivative of IFN-λ1, IFN-λ2, IFN-λ3 or IFN-λ4. (Item 17) 17. The use of interferon-lambda according to item 16, wherein the functional mimetic is pegylated. (Item 18) 18. Use of interferon-lambda according to item 17, wherein the functional mimetic is peg-interferon lambda-1a. (Item 19) The use of interferon-lambda according to claim 15, wherein the functional mimetic is an antibody. 16. The use of interferon-lambda according to item 15, wherein the functional mimetic is a small molecule chemical. (Item 21) 21. Use of interferon-lambda according to any one of items 14 to 20, wherein said interferon-lambda or functional mimetic activates the interferon-lambda receptor. (Item 22) 22. Use of interferon-lambda according to any one of items 14 to 21, wherein the fibrosis is renal fibrosis. (Item 23) 22. Use of interferon-lambda according to any one of items 14 to 21, wherein the fibrosis is pulmonary fibrosis. (Item 24) 22. Use of interferon-lambda according to any one of items 14 to 21, wherein the fibrosis is small intestinal fibrosis. (Item 25) 22. Use of interferon-lambda according to any one of items 14 to 21, wherein the fibrosis is dermal fibrosis. (Item 26) 22. The use of interferon-lambda according to any one of items 14 to 21, wherein the fibrosis is liver fibrosis. (Item 27) 20. A method of treating fibrosis comprising administering a therapeutically effective amount of interferon-lambda. (Item 28) 28. The method of claim 27, wherein the interferon-lambda is IFN-λ1, IFN-λ2, IFN-λ3 or IFN-λ4 or a functional mimetic thereof. (Item 29) 29. The method of claim 28, wherein the functional mimetic is a fragment, variant or derivative of IFN-λ1, IFN-λ2, IFN-λ3 or IFN-λ4. (Item 30) 30. The method of claim 29, wherein the functional mimetic is pegylated. (Item 31) 31. The method of claim 30, wherein the functional mimetic is pegylated interferon lambda-1a. (Item 32) 29. The method of claim 28, wherein the functional mimetic is an antibody. (Item 33) 29. The method of claim 28, wherein the functional mimetic is a small molecule chemical. (Item 34) 34. The method according to any one of items 27 to 33, wherein the interferon-lambda or functional mimetic activates an interferon-lambda receptor. (Item 35) 35. The method of any one of items 27 to 34, wherein the fibrosis is renal fibrosis. (Item 36) 35. The method of any one of items 27 to 34, wherein the fibrosis is pulmonary fibrosis. (Item 37) The method according to any one of items 27 to 34, wherein the fibrosis is small intestinal fibrosis. The method according to any one of items 27 to 34, wherein the fibrosis is dermal fibrosis. 35. The method of any one of items 27 to 34, wherein the fibrosis is liver fibrosis. (Item 40) 40. The method according to any one of items 27 to 39, wherein the interferon-lambda or functional mimetic is administered in combination with another therapeutically active compound. (Item 41) 41. The method of item 40, wherein the other therapeutically active compound is another antifibrotic therapeutic agent. [Brief description of the drawings]
[0011] [Figure 1]Figure 1 shows the identification of IL-28A as an antifibrotic hit in the adriamycin model of kidney disease. In the screening condition, mouse IL-28A (ILFNL2) was introduced into mice by hydrodynamic transfection as a pair of cDNAs (i.e., IL-28A cDNA and another undisclosed cDNA) (n=15 group size for all treatment groups) prior to administration of adriamycin by IV injection to induce chronic kidney disease. Control mice were transfected with saline only prior to adriamycin injection. Mice were monitored for up to 49 days and kidney hydroxyproline levels (Figure 1(a) and Figure 1(b)) and serum creatinine levels (Figure 1(c)) were measured at the end (no conditional survival data for primary screen). Figures for hydroxyproline (μg per mg kidney) and serum creatine (μg / mL) are box and whisker plots. The central horizontal line indicates the median of the data and the boxes extend from the 25th to the 75th percentile. Whiskers cover the typical range of the data.Normalized hydroxyproline (kidney collagen) shown as mean and +SEM error bars, ****p<0.0001, ***p<0.001, *p<0.05. [Diagram 2]Figure 2: Confirmation of IL-28A as an antifibrotic hit in the Adriamycin model of kidney disease. Mouse IL-28A (IFNL2) was introduced into mice by hydrodynamic transfection as a single cDNA (n=22 group size for all treatment groups) prior to administration of Adriamycin by IV injection to induce chronic kidney disease. Control mice were transfected with saline only prior to Adriamycin injection. Mice were followed for 49 days. At termination, kidney hydroxyproline levels (Figure 2(a) and Figure 2(b)) and serum creatine levels (Figure 2(c)) were measured and conditional survival data were recorded over the entire study period (Figure 2(d)). Figures for hydroxyproline (μg per mg kidney) and serum creatine (μg / mL) are box and whisker plots. The central horizontal line indicates the median of the data and the box extends from the 25th to the 75th percentile. The "whiskers" cover the typical range of the data. Normalized hydroxyproline (kidney collagen) is shown as mean and +SEM error bars, ****p<0.0001, ***p<0.001, *p<0.05. [Diagram 3]Figure 3: Identification of IL-28B as an anti-fibrotic hit in the adriamycin model of kidney disease. In the primary screen, murine IL-28B (ILFNL3) was introduced into groups of mice by hydrodynamic transfection as a cDNA pair (n=15 group size for all treatment groups) prior to adriamycin and the mice were monitored for up to 49 days, measuring kidney hydroxyproline (Figure 3(a) and Figure 3(b)) and serum creatinine (Figure 3(c)) levels at the end (no conditional survival data for this primary screen). Control mice were transfected with saline only prior to adriamycin injection. Figures for hydroxyproline (μg per mg kidney) and serum creatine (μg / mL) are box and whisker plots. The central horizontal line indicates the median of the data and the boxes extend from the 25th to the 75th percentile. The "whiskers" cover the typical range of the data. Normalized hydroxyproline (kidney collagen) is shown as mean and +SEM error bars, ****p<0.0001, ***p<0.001, *p<0.05. [Figure 4]Figure 4: Confirmation of IL-28B as an anti-fibrotic hit in the adriamycin model of kidney disease. Mouse IL-28B (IFNL3) was introduced into groups of mice by hydrodynamic transfection as a single clone (n=22 group size in each treatment group) prior to adriamycin and the mice were followed up for up to 49 days. Control mice were transfected with saline alone prior to adriamycin injection. At termination, kidney hydroxyproline levels (Figure 4(a) and Figure 4(b)) and serum creatine levels (Figure 4(c)) were measured and conditional survival data were recorded over the duration of the study (Figure 4(d)). Figures for hydroxyproline (μg per mg kidney) and serum creatine (μg / mL) are box and whisker plots. The central horizontal line indicates the median of the data and the boxes extend from the 25th to the 75th percentile. The "whiskers" cover the typical range of the data. Normalized hydroxyproline (kidney collagen) is shown as mean and +SEM error bars, ****p<0.0001, ***p<0.001, *p<0.05. [Diagram 5]Figure 5. Histological confirmation of IL-28B and IL-28A as antifibrotic in the adriamycin model of renal disease. At termination, kidneys from the studies described in Figures 2 and 4 were fixed in NBF, paraffin embedded, sectioned, and stained with either hematoxylin and eosin (H&E), picrosirius red (PSR), or Massons trichrome (MT). Slides were then imaged on a Hamamatsu slide scanner. Representative images of PSR-stained kidney sections are shown for IL-28B in Figure 5(a) for one untreated mouse, three saline adriamycin-treated mice, and three adriamycin-treated mice that also received IL-28B, and for IL-28A in Figure 5(f) for one untreated mouse, three saline adriamycin-treated mice, and three adriamycin-treated mice that also received IL-28A. All final mouse kidney slices from both IL-28B (10 untreated, 18 saline, and 22 IL-28B-treated) and IL-28A (8 untreated, 20 saline, and 19 IL-28A-treated) groups were imaged and the total area covered by PSR staining was estimated using the Definiens image analysis platform and is shown in Figure 5(b) and Figure 5(g), respectively. In addition, all slides were manually scored for fibrosis by separate experts in the field of fibrosis (2 scientists and 1 clinical pathologist) and pathology scores were calculated for IL-28B from H&E staining (Figure 5(c)) and PSR staining (Figure 5(d) and Figure 5(e)), and for IL-28A from PSR staining (Figure (h)) and MT staining (Figure (i)). Magnification = ×100. [Figure 6a]Figure 1 shows the effect of IL-28A in liver in an in vitro ECM fibrosis model. Human primary astrocytes (seeded at 1000 cells / well) were treated with IL-28A for 5 days in culture. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 6b] Figure 1 shows the effect of IL-28A in liver in an in vitro ECM fibrosis model. Human primary stellate cells in co-culture with human primary hepatocytes (1000 cells / well, seeded at 1:1 ratio) were treated with IL-28A for 5 days in culture. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 7a] Figure 1 shows the effect of IL28A and IL-28B in liver in vitro ECM fibrosis model and TGFβ. Human primary astrocytes (1000 cells / well) were treated with IL-28A or IL-28B in the presence of TGFβ at 250pg / ml for 5 days in culture. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data shows the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 7b]Figure 1 shows the effect of IL28A and IL-28B in liver in an in vitro ECM fibrosis model and TGFβ. Human primary stellate cells in co-culture with human primary hepatocytes (1000 cells / well, 1:1 ratio) were treated with IL-28A or IL-28B in the presence of TGFβ at 250pg / ml for 5 days in culture. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 8] High content images showing the effect of IL-28A and IL-28B on stellate cell-hepatocyte co-culture ECM stimulated with TGFβ1. Human primary stellate cells in co-culture with primary hepatocytes (1:1 ratio with a final cell concentration of 1000 cells / well) stimulated with TGFβ1 (250 pg / ml) were cultured alone (TGFβ1 co-culture) or treated with IL-28A or IL-28B at 10000, 1000, 100 or 10 ng / ml for 5 days. Images shown are from one representative field out of 16 for each condition. Magnification was performed with a ×10 objective. [Figure 9] Figure 1 shows the effect of IL-28A, IL-28B and IL-29 in a TGFβ1 stimulated small intestinal fibroblast ECM in vitro model. Human primary small intestinal fibroblasts (2000 cells / well) were treated with IL-28A, IL-28B or IL-29 (all at 10 ng / ml) in the presence of TGFβ (10 ng / ml) for 7 days in culture. Cells were removed and ECM proteins, fibronectin, collagen I&III and collagen IV were measured by immunofluorescence labelling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 10]Figure 1 shows the % inhibition of IL-28A and IL-28B in a skin keratinocyte-fibroblast co-culture ECM in vitro model. Human primary dermal fibroblasts from three individual batches were co-cultured with primary human keratinocytes (9:1 ratio with a final cell concentration of 1500 cells / well) and treated with increasing amounts of IL-28A or IL-28B for 7 days. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Normalized data from the three batches were calculated as % inhibition and plotted as mean ± SD. Cell viability was measured with PrestoBlue and the three fibroblast batches in co-culture with keratinocytes were normalized to the control co-culture and data were averaged to obtain fold change. [Figure 11] Figure 1. Effect of IL-28A, IL-28B and IL-29 in a skin keratinocyte-fibroblast co-culture ECM in vitro model. Human primary dermal fibroblasts in co-culture with primary human keratinocytes (9:1 ratio with a final cell concentration of 1500 cells / well) were treated with IL-29, IL-28A or IL-28B for 7 days at concentrations ranging from 1250 to 10000ng / ml of cytokines. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. Cell viability was measured with PrestoBlue. [Figure 12]High content images showing the effect of IL-28A, IL-28B and IL-29 in a skin keratinocyte-fibroblast co-culture ECM in vitro model. Human primary dermal fibroblasts from a representative donor in co-culture with primary keratinocytes (9:1 ratio with a final cell concentration of 1500 cells / well) were cultured alone (control) or treated with IL-29, IL-28A or IL-28B at 10000 or 1250 ng / ml for 7 days. Images show a combination of signals from fibronectin, collagen I&III, and collagen IV ECM matrix proteins and show one representative field out of a total of 16 fields per condition. Magnification was performed with a ×10 objective. [Figure 13] Figure 1 shows the effect of IL-28A and IL-28B in an IL-1α stimulated dermal fibroblast ECM in vitro model. Human primary dermal fibroblasts (1500 cells / well) stimulated with IL-1α (10 ng / ml) were treated with increasing amounts of IL-28A or IL-28B over 7 days of culture. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of four separate wells. Cell viability was measured with PrestoBlue. Data represents one of two different fibroblast batches. [Figure 14a]Figure 1 shows the effect of IL-28A, IL-28B and IL-29 in a renal RPTEC-fibroblast co-culture ECM in vitro model. Human primary renal proximal tubular epithelial cells (RPTEC) were co-cultured with primary human renal fibroblasts (1:1 ratio with a final seeding cell concentration of 2000 cells / well) for 7 days and treated with IL-29, IL-28A or IL-28B. Cells were removed and ECM proteins, fibronectin and collagen I&III were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of four separate wells. Cell viability was measured with PrestoBlue. Either IL-29, IL-28A or IL-28B was added to RPTEC and fibroblast co-cultures on day 0. [Figure 14b] Figure 1 shows the effect of IL-28A, IL-28B and IL-29 in a renal RPTEC-fibroblast co-culture ECM in vitro model. Human primary renal proximal tubular epithelial cells (RPTEC) were co-cultured with primary human renal fibroblasts (1:1 ratio with a final seeding cell concentration of 2000 cells / well) for 7 days and treated with IL-29, IL-28A or IL-28B. Cells were removed and ECM proteins, fibronectin and collagen I&III were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of four separate wells. Cell viability was measured with PrestoBlue. Either IL-29, IL-28A or IL-28B was added to RPTECs 24 hours prior to combination with fibroblasts. [Figure 14c]Figure 1 shows the effect of IL-28A, IL-28B and IL-29 in a renal RPTEC-fibroblast co-culture ECM in vitro model. Human primary renal proximal tubular epithelial cells (RPTEC) were co-cultured with primary human renal fibroblasts (1:1 ratio with a final seeding cell concentration of 2000 cells / well) for 7 days and treated with IL-29, IL-28A or IL-28B. Cells were removed and ECM proteins, fibronectin and collagen I&III were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of four separate wells. Cell viability was measured with PrestoBlue. Either IL-29, IL-28A or IL-28B was added to the fibroblasts 24 hours prior to combination with RPTEC. [Figure 15a] Figure 15 shows a comparison of the addition format to the effect of IL-28A, IL-28B, and IL-29 in a renal RPTEC-fibroblast co-culture ECM in vitro model. The data shown in Figure 14 was replotted to show the effect of IL-28A, IL-28B, and IL-29 in a renal co-culture cell line using three different addition protocols in one graph, where IL-28A, IL-28B, or IL-29 was added to a co-culture of RPTEC and HRF together (referred to as co-culture), added to RPTEC first and HRF introduced 24 hours later (referred to as RPTEC added first), added to HRF first and RPTEC introduced 24 hours later (referred to as HRF added first), and the co-culture continued for 7 days, respectively, with the fibronectin data replotted in Figure 15(a). ECM markers were analyzed using analysis of variance accounting for differences between addition order (co-cultures, RPTEC first, and HRF first) and dose (0-10000 ng / ml) for each cytokine. Post-analytical comparisons were performed and reported p-values were adjusted using Bonferroni correction. All analyses were performed using SAS v9.4 (SAS Institute). On the graphs, cytokine doses reaching significance are indicated with ****p<0.0001, ***p<0.001, **p<0.01, and *p<0.05. [Figure 15b] Figure 15(b) shows a comparison of the addition formats to the effect of IL-28A, IL-28B, and IL-29 in a renal RPTEC-fibroblast co-culture ECM in vitro model. The data shown in Figure 14 was replotted to show the effect of IL-28A, IL-28B, and IL-29 in a renal co-culture cell line using three different addition protocols in one graph, where IL-28A, IL-28B, or IL-29 was added to a co-culture of RPTEC and HRF together (referred to as co-culture), added to RPTEC first and HRF introduced 24 hours later (referred to as RPTEC added first), added to HRF first and RPTEC introduced 24 hours later (referred to as HRF added first), and the co-culture continued for 7 days, respectively, with the collagen I&III data replotted in Figure 15(b). ECM markers were analyzed using analysis of variance accounting for differences between addition order (co-cultures, RPTEC first, and HRF first) and dose (0-10000 ng / ml) for each cytokine. Post-analytical comparisons were performed and reported p-values were adjusted using Bonferroni correction. All analyses were performed using SAS v9.4 (SAS Institute). On the graphs, cytokine doses reaching significance are indicated with ****p<0.0001, ***p<0.001, **p<0.01, and *p<0.05. [Figure 16] Figure 14(b) shows high content images showing the effect of IL-28A, IL-28B, and IL-29 on renal RPTEC-fibroblast co-culture ECM. Human primary renal proximal tubular epithelial cells (RPTEC) in co-culture with primary human renal fibroblasts (1:1 ratio with a final cell concentration of 2000 cells / well at seeding) were cultured alone (control) or treated with IL-29, IL-28A, or IL-28B at 1000, 100, or 10 ng / ml for 7 days. Cytokines were added to RPTEC 24 hours prior to inclusion of fibroblasts in the culture as shown in Figure 14(b). Images shown are from one representative field out of a total of 16 fields for each condition. Magnification was performed with a ×10 objective. [Figure 17] Figure 2: Effect of IL-28A and IL-28B in a lung SA epithelial-fibroblast co-culture ECM in vitro model. Primary human small airway lung epithelial cells (SA epithelium) in co-culture with human IPF primary lung fibroblasts (1:1 ratio with a final cell concentration of 2000 cells / well at seeding) were treated with IL-28A or IL-28B for 7 days. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling and total ECM proteins were identified by flamingo pink staining. Imaging and quantification were performed on a Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. Cell viability was measured by PrestoBlue and fluorescence was read. [Figure 18] Figure 1 shows the protein and DNA sequences of IFNL1, IFNL2, IFNL3, and IFNL4. The protein sequences of IFNL1, IFNL2, IFNL3, and IFNL4 were obtained from the Uniprot database and the DNA sequences of IFNL1, IFNL2, IFNL3, and IFNL4 were from GenBank. [Figure 19] Figure 1 shows the effect of IL-28A and IL-29 in an in vitro human hepatic stellate cell and epithelial cell co-culture model of liver fibrosis. Human primary stellate cells and primary intrahepatic bile duct epithelial cells were co-cultured at 1000 cells / well (1:1 ratio) and treated with IL-28A or IL-29 for 5 days. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 20]Figure 1 shows the effect of IL-28A on podocyte survival in an in vitro 3D glomerular spheroid model of glomerulosclerosis. (a) 3D glomerular spheroids were composed of an inner core of human glomerular endothelial cells surrounded by GFP-labeled human podocytes. (b) Spheroids were grown in culture medium or treated with focal segmental glomerulosclerosis (FSGS) patient plasma in the presence of 15% final concentration plus or minus human IL-28A protein. At least five spheroids were imaged in each experiment and for each condition. (c) 2D maximum intensity projections (MIPs) of these spheroids were then analyzed using Definiens image analysis to define marker areas above a threshold intensity in the green channel under various culture conditions and plotted as cell marker area as a percentage of the total spheroid area. 7% of podocytes were GFP-labeled. [Figure 21]Figure 14. Hydrodynamic transfection of mouse IL-28B prevents fibrosis in a mouse unilateral ureteral obstruction (UUO) kidney fibrosis model. Mice were UUO operated (UUO operation control HDT, n=10), not operated (no-op, n=5), UUO operated but treated with IL-28B on day -1 for prophylactic administration (IL-28B HDT -1 day, n=10), or treated with IL-28B on day 7 for therapeutic administration (IL-28B HDT 7 days, n=10). All animals were sacrificed on day 21, kidneys were removed, fixed in NBF, paraffin embedded, sectioned, and stained with picrosirius red (PSR). Slides were then imaged on a Hamamatsu slide scanner. Representative images of PSR stained kidney slices are shown in Figure 21(a) for one normal mouse, two UUO surgery control mice, two UUO surgery and IL-28B treated on day -1 mice, or two UUO surgery and IL-28B treated on day 7 mice by hydrodynamic transfection. All final mouse kidney slices (5 x non-operated, 10 x UUO control, 10 x IL-28B on UUO day -1, and 10 x IL-28B treated on UUO day 7) were imaged and the total area covered by PSR staining was estimated using the Definiens image analysis platform reading either the total stained area (Figure 21(b)) or the area of high intensity staining (Figure 21(c)). Percentage of collagen area is shown as mean ± SEM by treatment group compared to SEAP control using Dunnett's multiple comparison test, **=p<0.01, ***p<0.001, and ****=P<0.0001. SEAP=secreted alkaline phosphatase control protein. [Figure 22] Figure 1 shows the effect of IL-29 in an in vitro human renal proximal tubule epithelial cell monoculture model of renal fibrosis. Human primary renal proximal tubule epithelial cells were co-cultured at 2000 cells / well and treated with IL-29 for 5 days. Cells were removed and ECM proteins, fibronectin, collagen I&III, and collagen IV were measured by immunofluorescence labeling with imaging and quantification by Cellomics Arrayscan. Data show the mean total intensity plotted as the mean ± SD of 4 separate wells. [Figure 23] FIG. 23(a): Treatment with human IL-29 by hydrodynamic transfection prevents tubulointerstitial fibrosis in a mouse unilateral ureteral obstruction model of renal fibrosis. C57BI / 6 mice were subjected to hydrodynamic transfection with a control vector containing SEAP (n=10) or a vector containing a human IL-29 construct (n=9). 24 hours after transfection, mice were subjected to unilateral ureteral obstruction (UUO) of the left kidney or were not operated on (n=4). After 7 days, hydrodynamic transfection was repeated and animals were sacrificed 19 days after UUO. FIG. 23(a): Serum samples were taken from mice on day 0 (24 hours after transfection) and again on day 19 and analyzed for human IL-29 protein. Human IL-29 levels were plotted compared to IL-29 levels in the day 0 UUO IL-29 group, the final D19 UUO SEAP group, and the final UUO IL-29 group. Kidneys were harvested, fixed in NBF, paraffin embedded, sectioned, stained with picrosirius red (PSR), and slides were then imaged on a Hamamatsu slide scanner. Figure 23(b) shows representative images from normal kidneys, UUO kidneys transfected with either a control SEAP-containing vector or a human IL-29-containing vector, shown at 100x (upper row) and 200x (lower row) magnification. All final mouse kidney slices (4 x non-operated, 10 x UUO SEAP control, 9 x UUO IL-29 on day -1) were imaged and the total area covered by PSR staining was estimated using the Definiens image analysis platform reading the total stained area (Figure 23(c)). Percentage of collagen area is shown as mean ± SEM by IL-29 treatment group compared to UUO+SEAP control group using uncorrected Fisher's LSD comparison test, **=p<0.01. SEAP=secreted alkaline phosphatase control protein DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Unless otherwise defined, all scientific and technical terms used herein are within the meaning of the present invention. As used herein, the terms "a", "b", "c", "d" and "e" have the same meaning as commonly understood by one of ordinary skill in the art. All publications and patents cited are incorporated by reference.
[0013] It will be appreciated that any of the embodiments described herein may be combined. Wax.
[0014] The present invention provides interferon-lambda for use in the treatment of fibrosis. Ming also provides the use of interferon-lambda for the preparation of a medicament for the treatment of fibrosis. The present invention includes administering a therapeutically effective amount of interferon-lambda. Further provided is a method for treating fibrosis.
[0015] Interferons (IFNs) play a key role in protecting the host from viral infections and regulating immune responses. They are an important class of cytokines with diverse roles in the regulation of immune responses to three different types of cytokines: Ferons are recognized based on their structural features, receptor usage, and biological activity. There are three types of IL-16 (types I, II, and III), and their roles in host defense are unclear. varies.
[0016] Type I IFNs (IFN-α / β / ω / ε / κ in humans) have strong antiviral activity. , which can induce potent antiviral responses in a wide variety of cell types (Huang et al. l 1993). IFN-α / β is a cellular signaling regulator that binds IFNαR (IFNAR1 subunit and IFN It binds to a heterodimeric transmembrane receptor called the AR2 subunit Upon ligand association, it activates the kinases JAK1 and TYK2, which then This phosphorylates specific tyrosines in the intracellular domain of the receptor. , docking sites for STAT1 signaling molecules and STAT2 signaling molecules These are then recruited and subsequently phosphorylated. AT recruits IFN regulatory factor 9 (IRF9), which together recruit IFN-stimulated gene factor 3 (IFN-SR3) (ISGF3), which enters the nucleus and activates the transcription of IFN-stimulated genes (ISGs). Drive.
[0017] The type II class contains only IFN-γ, which is involved in the proliferation and proliferation of Mycobacterium tuberculosis. In host defense against pathogenic microorganisms such as Streptococcus tuberculosis, It stimulates cell-mediated immune responses that are important in tumor immunity (Bach et al 1997). Th1 type plays a central role in the immune response and amplifies the antiviral activity of type I IFN Type I and II IFNs are classified as cytokines. Thus, type I and type II IFNs play important roles in the regulation of infection and tumor In order to defend the host against both innate and adaptive immune responses, They work together to activate the
[0018] IFN is a cytokine that regulates the production of 6 IL-10-related cytokines: IL-10, IL-19, IL Greater expression of type II cytokines, including IL-20, IL-22, IL-24, and IL-26 family (Kotenko 2002), which share a common extracellular domain They are classified together because they signal through receptors that share a common motif. These receptors include the type II cytokine receptor family (CRF2), which typically Specifically, two different receptor chains (α-receptor subunit and β-receptor subunit) It is a heterodimer composed of a mitochondrial unit (Stahl et al 1993). In particular, the α subunit is the major cytokine-binding protein, and the β subunit is the highly responsive It is required for compatibility binding site formation and signal transduction.
[0019] Type III IFNs, or IFN-lambda, are a more recent addition to the CRF2 family. This represents a structural feature of IL-10-related cytokines and is restricted compared to type I IFNs. Induce antiviral activity in selected cell populations (i.e., epithelial cells and certain immune cells) (K otenko et al, 2003; Sheppard et al, 2003). Hi In humans, the type III IFN family consists of four closely related proteins: IFN-λ 1, -λ2, -λ3 and -λ4 (IL-29, IL-28A, IL-28B and The mouse is composed of IFN-λ2 and -λ3, whereas the mouse is composed of IFN-λ4 and -λ5. (IL-28A and IL-28B, respectively). These have a very high homology. The amino acid identity between IFN-λ2 and IFN-λ3 is approximately 96%, and that between IFN-λ1 and IFN-λ2 is approximately 96%. The identity between IFN-λ4 and IFN-λ2 / λ3 is approximately 81%. Although most closely related, these proteins share only about 30% identity, I FN-λ4 is mainly present intracellularly and is poorly secreted in humans (Hong et al. al 2016).
[0020] The IFN-λ receptor complex contains a unique IFN-λ receptor chain 1 (IFN-λR1 or is IL-28RA) and the shared IL-10 receptor chain 2 (IL-10R2 or IL-1 0Rβ) is composed of one of four ligands, the IFN-λ receptor complex. Upon assembly into the fusion complex, JAK1 and TYK2 are activated, and the transcription factors STAT1 and STAT 2 and IRF9 are activated to form IFN-stimulated gene factor 3 (ISGF3). ISGF3 inhibits many genes associated with antiviral phenotypes (e.g., OAS1, MX1, Hundreds of proteins, including EIF2AK2 (double-stranded RNA-activated protein kinase) and IRF7 Binding to the IFN-stimulatory element (ISRE) in the promoter of IFN-stimulated genes (ISGs) Comparative cDNA microarray analysis revealed that type III IFN The repertoire of genes induced by type I IFNs (IFN-α / β ) has been shown to be essentially identical to that induced by In conclusion, despite the use of different receptors, type I IFN and Both type III and type III IFNs activate ISGF3 (Zhou et al 2007). , thus eliciting a similar transcriptional response.
[0021] The patterns of gene expression induced by either type I or type III IFNs were non- Although always similar, the relative magnitude of gene expression induced by IFN-α varied with the IFN This is due to the fact that the β-catenin receptor is mediated via type I receptors versus type III receptors. These may reflect differences in the relative strength of signaling between the two ligands, or This may simply reflect differences in the expression levels of each receptor.
[0022] The crystal structure of IFN-λ reveals a four-helix bundle structure typical of type II cytokines. The closest structural analogue of IFN-λ is IL-22 (Gad et al. 2013). 09) IFN-λ and IL-22 inhibited the epithelial cell proliferation and proliferation by viral and bacterial infections, respectively. These findings suggest that IFN-λR1 receptor may have a parallel function in protecting the tissue. The binding sites on the chains are well conserved among all four IFN-lambda species, but not on IL-10R2. The binding site for IFN-λ is poorly defined (Miknis et al 2010). R1 consists of two distinct fibronectin type III domains of approximately 100 amino acids each. The ligand-receptor interface consists of helix A, loop AB and and helix F, mainly derived from the N-terminal domain and interdomain hinge region of IFN-λR1. The binding mode between the ligand and the receptor is mediated through hydrogen bonds. Supporting initial long-range ionic interactions, followed by hydrophobic interactions to complete the fit. The interaction continues.
[0023] IFNλ is expressed by a variety of hematopoietic and epithelial cells in response to viral infection. The transcription factor NF-κB is a pattern recognition receptor that detects invading viruses on mucosal epithelial surfaces. B. Initiates transcriptional responses via IRF3, IRF7, and Med23 (Osterlun d et al 2007, Griffiths et al 2013). The role of type I and type III IFNs in mediating antiviral defense against viruses and Depending on the point of entry, the intestinal epithelial cells have been shown to be both redundant and unique. The IFN-dependent IL-1 receptor agonists are exclusively resistant to type III IFN, which mediates the control of epithelial-tropic viruses such as HIV-1. Reovirus infection begins in the intestinal epithelium, but In mice, type III IFNs can penetrate the intestinal epithelium and cause systemic infection, and Although limiting early replication in epithelia, type I IFNs are essential for preventing systemic infection (Ma There is a certain degree of redundancy between the two IFN systems. In the pulmonary arteries, the distinction between type I and type III IFNs is less clear (Mord Therefore, airway epithelia express receptors for both IFN types. The intestinal epithelium expresses only the IFN-λ receptor, whereas the intestinal epithelium expresses only the IFN-λ receptor.
[0024] IFN-λR1 receptor expression is, in certain scenarios, primarily located on epithelial cells Specific immune cell subsets (e.g., monocyte-derived macrophages, plasmacytoid dendritic cells, and Activation of IFN-λR1 in NK cells is restricted to IFN-λ. associated with maximal production and antitumor activity, which may occur synergistically with other stimuli or in other cell types. (Souza-Fonseca-Guimar aes et al. 2015). IFN-λR1 expression is restricted to immune and epithelial cells. Although the immunomodulatory effects of type III IFN are limited due to the presence of If the effect is sufficient to control the virus, it is a very effective antiviral. In contrast to the ubiquitous activity of type I IFNs during responses to infection, It is more relevant in the control of severe or systemic infections where immune activation is required.
[0025] The following references provide information on signaling between type I and type III interferons: These findings explain the differences in drug delivery and biological effects: Wack et al. 2015, Chow & Gale 2015, Hemann et al 2017, Brogg i et al 2017, Blumer et al 2017, Chiriac e t al 2017, Bhushal et al 2017, Andreakos e t al 2017 and Bhushal et al 2017.
[0026] The contribution of IFN-λ to antiviral therapy has been demonstrated in preclinical models in mice and chimpanzees. Based on available data and on primary human stem cells infected with Hepatitis C virus (HCV), Based on the available in vitro data (Thomas et al. 2012, Park et al. t al 2012) as well as available data from human clinical trials (PhII BMS data The range of viruses that can be targeted by IFN-λ is as follows: Including but not limited to: Influenza A / B, Severe Acute Respiratory Syndrome (SAR) S), coronavirus, H1N1, human immunodeficiency virus (HIV), herpes simplex virus Hepatitis C virus type 2 (HSV2), cytomegalovirus (CMV), Middle East respiratory syndrome (MERS) ), norovirus, rotavirus and Ebola (Eslam and George 20 15; Gresser 2015). All of these viruses target epithelial entry points. In therapeutic intervention, the IFN-λR1 receptor complex can be activated at this access point. These may be targets of IFN-λ.
[0027] Numerous preclinical studies have demonstrated that IFN-λ is an effective anti-cancer agent in various tumor types (e.g., hepatocellular carcinoma, melanoma, Antitumor activity in esophageal cancer, neuroendocrine tumors, colorectal cancer, lung adenocarcinoma, and Burkitt's lymphoma It has been demonstrated that (Steen et al. 2010). Antitumor mechanism of IFN-λ The mechanism is thought to be involved in tumor cell induction of apoptosis, as well as innate and adaptive immune stimulatory activity. IFN-λ is a direct effect on immune cells to boost both immune activity and the tumor microenvironment. Signaling through the IFN-λR1 receptor was induced in the mouse model of tumors. In IFN-λR1 knockout mice, which are more susceptible to sarcoma formation and death due to IFN-λ treatment delayed lethality and The development of sarcomas was suppressed (Numasaki et al 2007). In this context, IFN-λ is a novel immune checkpoint inhibitor that is more effective than current IFN-α. It is used to complement chemotherapy or to supplement conventional anticancer drugs (e.g., bortezomib, temozolomide, It may be envisaged as an adjuvant for cyclosporine or 5-FU (Guenterbe rg et al 2010, Li et al 2010).
[0028] Genetic and functional evidence supports the role of inflammatory diseases (e.g., asthma, psoriasis, and rheumatoid arthritis). In a mouse model of asthma, IFN-λ inhibits the Minimize disease severity, reduce eosinophil infiltration, and suppress Th2 cytokines and Th 17 A Th1 immune skewing effect away from cytokines has been demonstrated (Koltsida et al. In a mouse collagen-induced arthritis model, IFN-λ2 treatment increased This suppresses the IL-1 and IL-17 responses, inhibits disease, and induces neutrophil recruitment. In psoriatic lesions, Th17 cells are involved in the I It has been shown that IFN-lambda is a source of IFN-lambda, which is a Th2 cytokine that inhibits IL-1 3 (Wolk et al. 2013). The role of IFN-λ in this process remains unclear.
[0029] Three groundbreaking genome-wide association studies (GWAS) of HCV have revealed that IFN-λ Single nucleotide polymorphisms (SNPs) in the region were associated with PEGylated IFN-λ1 / ribavirin (PEG-IFN-λ1 / ribavirin) The strongest response to both N / RBV therapy and spontaneous clearance of chronic HCV infection This SNP is associated with the IFNL3 / IFNL4 gene. Located at the 5' locus, it is effective against all HCV genotypes and in all geographic locations It has been shown that (Ge et al. 2009, Suppiah et al. 2009, Tanaka et al. 2009). All antiviral therapies (first generation in predicting treatment outcomes for antivirals (both first- and second-generation direct-acting antivirals) The role of the IFNL3 / IFNL4 genotype has also been implicated in CMV, HSV and Epstein-B A comprehensive list of other viral infections such as arrvirus (EBV) as well as HCV / HIV and and coinfection with HCV / HBV (Rallon et al. 2010, Guo et al. t al 2013). Data support the notion that viral infection in various organs, particularly those of epithelial origin, This is consistent with a major role for IFN-λ in regulating
[0030] In hepatitis C virus infection, hepatitis B virus infection, and nonalcoholic fatty liver disease Two SNPs (i.e., rs12979860 and rs8099917) were associated with liver fibrosis. Evidence for the role of genomic DNA (e.g., "responder" genotypes) and promotion of liver inflammation and fibrosis Exist (Bochud et al. 2012, Eslam et al. 2015) .
[0031] Two functional variants in the IFNL3 / IFNL4 region are the first GWAS findings There are many other contributing factors that have been linked but not yet identified. The first SNP controls the production of IFN-λ4 and also predicts HCV clearance. G / TT (rs368234815) (Prokunina-Olsson et al. al 2013). The ancestral “ΔG” allele encodes a functional IFN-λ4 and is HC V clearance and thus increased viral load, whereas the ( The more recent "TT" allele (in evolutionary terms) is the open reading frame of IFNL4. Disruption of REME (disruption of protein expression) is associated with improved viral clearance This apparent paradox is mainly due to the subcellular localization and insufficient secretion of IFNL4, as well as and IFNL4 can inhibit the secretion and thus the function of other IFN-λ family members. A second SNP (rs4 803217) affects the stability of IFNL3 messenger RNA (McF The role of these variants in predicting liver fibrosis The role of these is unknown, especially in non-HCV cohorts, but these Linkage disequilibrium, so further studies are needed to show whether there is any association. is necessary.
[0032] In summary, to date, IFN-λ has been shown to have antiviral and antitumor activities, as well as immune-inflammatory functions. In the present invention, the inventors have demonstrated that IFN has a homeostatic effect as well as a potent inhibitor of IFN-dependent activating properties. We have unexpectedly found that β-lambda has direct antifibrotic effects both in vitro and in vivo. The examples disclose that interferon-lambda protein inhibits the in vivo function of mice. In chronic kidney disease models, as well as in the liver, small intestine, skin, kidney and In an in vitro human fibrosis model with relevant primary cells derived from the lung and pulmonary organ systems, Thus, this protein has an antifibrotic effect on multiple types of fibers. US20130232633A1 - Novel anti-fibrotic agent with unexpected potential for the treatment of fibrotic diseases - Google Patents The results can be used to design treatments for
[0033] The terms interferon-lambda (IFN-λ) (singular) and interferon-lambda (IFN-lambda) (plural) refers to cytokines of the interferon-lambda family. Interferon-lambda protein and interferon-lambda protein are used interchangeably herein. The terferon-lambda receptor is also known by many other synonyms, as shown in Table 1. It is known. [Table 1]
[0034] In one embodiment, the interferon-lambda is IFN-lambda. The interferon-lambda is IFN-λ2. In one embodiment, the interferon-lambda is IFN-lambda. The answer is 4.
[0035] Amino acid sequences and DNA sequences of IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4 Sequence A is shown in FIG.
[0036] IFN-λ may be used in the form of a fusion protein, such as an Fc fusion protein. The protein consists of the Fc domain of an antibody (e.g., IgG) fused to IFN-λ. The Ic fusion protein forms a dimer as a result of the association of the Fc domains. FN-λ can be in dimeric and monomeric forms.
[0037] Functional mimics In one embodiment, interferon-lambda is a functional mimetic of IFN-lambda. In one embodiment, interferon-lambda is a functional mimetic of IFN-lambda. In one embodiment, interferon-lambda is a functional mimetic of IFN-lambda3. In one embodiment, interferon-lambda is a functional mimetic of IFN-lambda. .
[0038] The term "functional mimetic" refers to a compound that has the same or a similar biological effect as the wild-type protein. For example, a functional mimetic of interferon-lambda is interferon-lambda. Activates the IFN-lambda receptor and drives transcription of IFN-stimulating factors
[0039] In one embodiment, the functional mimetic is an in vivo model of fibrosis, as described in Example 1. In one embodiment, the functional mimetic may reduce hydroxyproline levels in the mitochondrial cell line. Fibrinogen activator (FAN) was used to induce fibronectin expression in an in vitro model of fibrosis as described in Example 2. and / or may inhibit collagen deposition.
[0040] In one embodiment, the functional mimetic of interferon-lambda is a fragment of IFN-lambda. In one embodiment, the functional mimetic of interferon-lambda is a fragment of IFN-λ2. In one embodiment, the functional mimetic of interferon-lambda is IFN-λ3. In one embodiment, the functional mimetic of interferon-lambda is a fragment of IFN- It is a fragment of λ4.
[0041] In one embodiment, the functional mimetic of interferon-lambda inhibits the barrier function of IFN-λ1. In one embodiment, the functional mimetic of interferon-lambda is IFN-lambda. 2. In one embodiment, the interferon-lambda functional mimetic is In one embodiment, the functional variant of interferon-lambda is The mimetics are variants of IFN-λ4.
[0042] Variant interferon-lambda is a variant of one of the specific sequences shown in FIG. For example, the variant may be the variant of FIG. It may be a substitution, deletion or addition variant of any of the amino acid sequences. A fragment of IFN-λ may be, for example, more than 50 amino acids, more than 100 amino acids, or more than 150 amino acids. The amino acid sequence may be greater than 100 amino acids in size.
[0043] Variant interferon-lambda has a 1:1 amino acid sequence as compared to the specific amino acid sequence of FIG. 1, 2, 3, 4, 5, up to 10, up to 20 or more (generally up to 50) A "deletion" variant may include substitutions, deletions and / or additions of amino acids of the individual amino acids. deletion of amino acids, small groups of amino acids (e.g., 2, 3, 4 or 5 amino acids) deletion of a specific amino acid domain or a larger region of amino acids (e.g., "Substitutional" variants generally include one or more amino acids that have been replaced with one or more amino acids. This includes replacing an amino acid with an equal number of amino acids, and making conservative amino acid substitutions. For example, an amino acid may be substituted with a substitute amino acid having similar properties (e.g., another basic amino acid, another of acidic amino acids, other neutral amino acids, other charged amino acids, other hydrophilic amino acids, other hydrophobic amino acids another polar amino acid, another aromatic amino acid, or another aliphatic amino acid) Some of the 20 main amino acids that can be used to select appropriate substitutes are The characteristics are shown in Table 2. [Table 2]
[0044] Variant interferon-lambda has a sequence similar to that of FIG. 18, but is more similar to that of FIG. or greater than about 70%, e.g., 75 or 80%, typically greater than about 85%, e.g., about The variants may have amino acid sequences with greater than 90 or 95% amino acid identity. , at least about 90%, 91%, 92%, 93%, 94%, 95% for the sequence of FIG. Variants may retain about 6%, 96%, 97%, 98% or 99% identity. 0% to about 99% identity, about 80% to about 99% identity, about 90% to about 99% identity, or about 95% to about 99% identity. This level of amino acid identity is consistent with the It may be found throughout the entire sequence of the sequence of SEQ ID NO: or throughout a portion of this sequence, for example, about 20 , 30, 50, 75, 100, 150, 200 or more amino acids It can be seen as.
[0045] The term "identity" as used herein refers to any particular position in the aligned sequences. The term "similarity" is used herein to refer to the identity of amino acid residues between the sequences. When used in the above, it is possible to distinguish between amino acid residues at any particular position in the aligned sequences. indicates that the groups are of similar type. For example, leucine can be substituted for isoleucine or valine. Other amino acids that can often substitute for one another include: These include, but are not limited to: Phenylalanine, tyrosine, and tryptophan (amino acids with aromatic side chains) · Lysine, arginine, and histidine (amino acids with basic side chains); Aspartic acid and glutamic acid (amino acids with amide side chains); and · Cysteine and methionine (amino acids with sulfur-containing side chains).
[0046] In one embodiment, the functional mimetic of interferon-lambda is a derivative of IFN-λ1. In one embodiment, the functional mimetic of interferon-lambda is In one embodiment, the functional mimetic of interferon-lambda is an IFN- In one embodiment, the functional mimetic of interferon-lambda is a derivative of I It is a derivative of FN-λ4.
[0047] In one embodiment, the interferon-lambda has one of the specific sequences shown in FIG. In one example, the derivative may be or may include a derivative of the naturally occurring It may include structural analogs of amino acids. Alternatively, the amino acids may be modified, e.g., labeled. may be added.
[0048] In one embodiment, the interferon-lambda of the present invention is pegylated, i.e. Interferon-lambda is covalently attached to poly(ethylene glycol) (PEG). Methods for producing pegylated proteins are known in the art and are described, for example, in Chapm et al. an A et al.,2002,Advanced Drug Delivery See Reviews 54:531-545.
[0049] In one embodiment, the pegylated interferon-lambda is pegylated interferon lambda- 1a “Lambda” (Andersen et al., 2013). “Lambda” is, Originally from ZymoGenetics (now part of Bristol-Myers Squibb) It is a type III interferon drug currently under investigation, developed by Eppendorf (a wholly owned subsidiary of Eppendorf). The treatment was licensed to Eiger Biopharmaceuticals in 2016. The drug is currently in clinical development for the treatment of chronic hepatitis delta virus (HDV) infection. .
[0050] In one embodiment, the interferon-lambda functional mimetic is an antibody.
[0051] The antibody molecule of the present invention may be a complete antibody molecule having full-length heavy and light chains, or a fragment or a mixture thereof. The term "antigen-binding portion" of an antibody refers to a portion of an antibody that selectively binds to an antigen. The term refers to one or more fragments of an antibody that retain the antigen-binding function of the full-length antibody. It has been found that antibodies and fragments and antigen-binding portions thereof can be used. , including but not limited to Fab, modified Fab, Fab', modified Fab', F(ab')2, F v, single domain antibodies (e.g., VH or VL or VHH), scFv, bivalent antibodies, trivalent antibodies or tetrabodies, bis-scFvs, bibodies, tribodies, tetrabodies, and epitope-binding fragments of any of the above (e.g., Holliger and Hudson,2005,Nature Biotech.23(9):11 26-1136;Adair and Lawson,2005,Drug Design (See Reviews-Online 2(3), 209-217.) Methods for generating and producing antibody fragments from such antibodies are known in the art (see, for example, Verm et al., J. Immunol. 1999, 143:1311-1323). a et al., 1998, Journal of Immunological M (See Methods, 216, 165-181.) Other examples for use in the present invention include As antibody fragments, there are mentioned antibody fragments as disclosed in WO 2005 / 003169 and WO 2005 / 0 As explained in Brochure No. 03170 and Brochure No. 2005 / 003171 Fab fragments and Fab' fragments, and Examples of suitable antibodies include Fab-dAb fragments, which are described in the article. Multivalent antibodies contain multiple specificities. The antibody may be multispecific or monospecific (see, for example, WO 92 / 22853). (See, for example, U.S. Pat. No. 5,393,365 and U.S. Pat. No. 5,393,365). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the fragments can be isolated from intact antibodies. The compounds can be screened for usefulness in the same manner as described above.
[0052] The antibodies of the present invention are functional mimetics of interferon-lambda and are identical to the wild-type protein. The antibody induces the same or a similar biological effect. For example, the antibody inhibits the interferon-laserase inhibitor It can bind to an epitope on the Muda receptor and activate receptor signaling to induce IFN- Drives transcription of stimulatory genes.
[0053] In one embodiment, the interferon-lambda derivative is a small molecule chemical (e.g., (chemicals with molecular weights less than 900 Daltons).
[0054] Screening chemical libraries to identify small molecule chemicals that may be potential drug candidates Methods for scanning are known in the art. For example, chemical scanning, as described in Example 2, The library will be tested in ligand-receptor binding assays or cell culture models of organ fibrosis. It can be tried.
[0055] Fibrotic diseases Examples of fibrotic diseases that can be treated using the interferon-lambda of the present invention include These include, but are not limited to: interstitial lung disease, pulmonary fibrosis, e.g., idiopathic pulmonary fibrosis, Fibrosis, silicosis, hypersensitivity pneumonitis, nonspecific interstitial pneumonia, rheumatoid lung, scleroderma, chronic obstructive pulmonary disease fibrosis; renal fibrosis (e.g., chronic glomerulonephritis); eruonephritis, tubulointerstitial nephropathy, and genetic disorders of the kidney, e.g. Diabetic nephropathy, hypertensive nephrosclerosis, focal segmental glomerulosclerosis, IgA nephropathy, mesangium Proliferative glomerulonephritis, membranous nephropathy, renovascular disease, polycystic kidney disease, chronic allograft nephropathy, and Goodpasture's disease; liver fibrosis and cirrhosis, e.g., primary sclerosing cholangitis, primary biliary Alcoholic cirrhosis, alcohol-induced liver disease, and nonalcoholic fatty liver disease (e.g., fatty liver disease caused by other fatty acids) liver disease); as well as endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, encapsulated abdominal Intestinal stenosis may occur in membranous fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease (and other Diseases that may occur include keloids, myocardial infarction, scleroderma, systemic sclerosis, and arthrofibrosis.
[0056] In one embodiment, the fibrosis is renal fibrosis (wherein the IFN-λ is IFN-λ1, In one embodiment, the fibrosis is pulmonary fibrosis (in this case, IFN-λ is IFN-λ1, IFN-λ2, IFN-λ In one embodiment, the fibrosis is small intestinal fibrosis (which may be IFN-λ3, IFN-λ4, or IFN-λ5). In this case, the IFN-λ is IFN-λ1, IFN-λ2, IFN-λ3, or IFN-λ4. In one embodiment, the fibrosis is dermal fibrosis (in which case IFN-λ may be In one embodiment, the IFN-λ1, IFN-λ2, IFN-λ3, or IFN-λ4. In this case, the fibrosis is liver fibrosis (IFN-λ is IFN-λ1, IFN-λ2, etc.) , IFN-λ3, or IFN-λ4). In one embodiment, the fibrosis is peritoneal fibrosis. (In this case, IFN-λ is IFN-λ1, IFN-λ2, IFN-λ3, or I In one embodiment, the fibrosis is pancreatic fibrosis (in which case IFN-λ4 may be used). -λ can be IFN-λ1, IFN-λ2, IFN-λ3, or IFN-λ4). In one embodiment, the fibrosis is atherosclerosis (in which case IFN-λ is The IFN-λ1, IFN-λ2, IFN-λ3, or IFN-λ4.
[0057] In one embodiment, the fibrosis is renal fibrosis, pulmonary fibrosis, small intestinal fibrosis, skin fibrosis, or liver fibrosis. , peritoneal fibrosis, pancreatic fibrosis, and atherosclerosis.
[0058] In one embodiment, the fibrosis is renal fibrosis, pulmonary fibrosis, small intestinal fibrosis, skin fibrosis, peritoneal fibrosis, pancreatic fibrosis, and atherosclerosis.
[0059] In one embodiment, the fibrosis is not associated with a microbial infection (eg, a viral infection). Therefore, the subject to be treated in accordance with the present invention is one who is not suffering from an infection, such as a viral infection. For example, the subject may be a patient suffering from a viral infection known to be treated with IFN-λ. The subject may be free of hepatitis infection. Hepatitis or Hepatitis C; Influenza virus; Severe Acute Respiratory Syndrome (SARS) Virus; Coronavirus; Human immunodeficiency virus (HIV); Herpes simplex virus type 2 (HSV2); Cytomegalovirus (CMV); Middle East Respiratory Syndrome (MERS) virus may not be infected with norovirus, rotavirus, or Ebola virus .
[0060] Pharmaceutical Compositions, Dosages, and Administration Regimens The interferon-lambda or a functionally active fragment or derivative thereof of the present invention is The pharmaceutical composition is usually sterile and may contain a pharma- ceutical acceptable adjuvant. May further include bundt and / or carrier
[0061] As used herein, a "pharmaceutical acceptable carrier" refers to any Any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption retarding agents The carrier may be suitable for parenteral administration, e.g., intravenous, intramuscular, Intradermal, intraocular, intraperitoneal, subcutaneous, spinal, or other parenteral routes of administration, such as injection or infusion Alternatively, the carrier may be suitable for parenteral administration (e.g., via topical administration). The carrier may be suitable for oral administration. Depending on the pathway of administration, interferon-lambda or a functionally active fragment or derivative thereof It is coated with a material that protects it from the action of acids and other natural conditions that may inactivate it. It is possible.
[0062] The pharmaceutical compositions of the present invention may include one or more pharma- ceutically acceptable salts. "Acceptable salts" are salts that retain the desired biological activity of the parent compound and do not contain any undesirable toxicological properties. Examples of such salts include acid addition salts and base addition salts. Can be obtained.
[0063] Pharmaceutically acceptable carriers include aqueous carriers or diluents. Examples of suitable aqueous carriers that may be used include water, buffered water and saline. Examples include ethanol, polyols (e.g., glycerol, propylene glycol, poly polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, e.g. Examples include olive oil, and injectable organic esters such as ethyl oleate. In this case, isotonic agents, for example, sugars, polyalcohols (e.g., mannitol, It may be desirable to include sodium chloride, sodium phosphate phosphate, sorbitol, or sodium chloride.
[0064] Therapeutic compositions generally must be sterile and stable under the conditions of manufacture and storage. The composition may be formulated as a solution, microemulsion, liposome, or other suitable formulation for high drug concentration. It may be formulated as other ordered structures.
[0065] The pharmaceutical compositions of the invention may contain additional active ingredients.
[0066] Also within the scope of the present invention are interferon-lambda and instructions for use. The kit may also include one or more additional reagents (e.g., those discussed above). Additional therapeutic or prophylactic agents may also be included.
[0067] The interferon-lambda or a formulation or composition thereof of the present invention may be used for the prevention of fibrotic diseases. The therapeutic agent may be administered for topical and / or therapeutic treatment.
[0068] In one embodiment, the treatment of a fibrotic disease is a therapeutic treatment. In therapeutic applications, the compounds are administered to A subject already suffering from a disorder or condition described above is given treatment with any of the following: in an amount sufficient to cure, alleviate, or partially arrest one or more of Such therapeutic treatment may result in a reduction in the severity of symptoms of the disease or a symptom-free period. An amount sufficient to accomplish this may result in an increase in the frequency or duration of "super-effective amount" is defined as a "super-effective amount."
[0069] In one embodiment, the treatment of a fibrotic disease is a prophylactic treatment. In prophylactic applications, the formulation is administered A subject at risk for a disorder or condition described above is administered a treatment with a symptom of the condition or one of its symptoms. The compound is administered in an amount sufficient to prevent or reduce the subsequent effects of the compound or compounds. An amount adequate to accomplish this is defined as a "prophylactically effective amount."
[0070] Effective amounts for each purpose will depend on the severity of the disease or injury, as well as the weight and general state of the subject. I guess so.
[0071] The subject of administration may be a human or a non-human animal. The term "non-human animal" includes all vertebrate animals. For example, mammals and non-mammals (e.g., non-human primates, sheep, dogs, cats, This includes animals such as horses, cows, chickens, amphibians, and reptiles. Administration to humans is typical.
[0072] The antibodies / modifiers or pharmaceutical compositions of the invention can be prepared by one or more of a variety of methods known in the art. Multiple species may be used and administered via one or more routes of administration. As such, the route and / or mode of administration will vary depending on the desired results. Examples of routes of administration of the composition include intravenous, intramuscular, intradermal, intraocular, intraperitoneal, subcutaneous, spinal, or other. The term "parenteral administration route" includes parenteral administration routes, such as parenteral administration routes by injection or infusion. "Parenteral administration," as used herein, refers to enteral administration, usually by injection, and topical administration. Alternatively, the pharmaceutical compositions of the present invention can be administered parenterally (e.g., topically). The pharmaceutical composition of the present invention may be administered via the intradermal, epidermal, or mucosal route of administration. may be for oral administration.
[0073] The appropriate dosage of the pharmaceutical composition of the present invention can be determined by a skilled physician. The actual dosage level of the active ingredient in the pharmaceutical composition may be adjusted to a level that is consistent with the intended effect without causing toxicity to a particular patient. and an active ingredient effective to achieve the desired therapeutic response for the patient, composition, and mode of administration. The dosage level selected will depend on various pharmacokinetic factors. These may vary depending on, for example, the activity of the particular composition of the invention used, the route of administration, the time of administration, The excretion rate of the particular compound, the duration of treatment, and the use in combination with the particular composition used. Other drugs, compounds, and / or materials used, age, sex, weight, condition, and general health as well as the past medical history of the patient being treated, and similar factors well known in the medical arts. cormorant.
[0074] Suitable doses are, for example, from about 0.01 μg to about 100 μg per kg of the body weight of the patient being treated. 0 mg / kg, typically in the range of about 0.1 μg to about 100 mg / kg of body weight. For example, a suitable dosage may be about 1 μg to about 10 mg per kg of body weight per day. g, or from about 10 μg to about 5 mg per kg of body weight per day.
[0075] Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single dose may be administered, or multiple divided doses may be administered over time. or relatively decreased or increased as indicated by the urgency of the therapeutic situation. As used herein, unit dosage form refers to a physical form suitable for a unitary administration to a subject to be treated. "pharmaceutical" refers to a compound that is essentially a discrete unit, each of which, in association with the required pharmaceutical carrier, produces a desired therapeutic effect. The formulation contains a predetermined amount of active compound calculated to provide a
[0076] Administration may be in a single dose or multiple doses. Multiple doses may be administered in the same or via different routes and to the same or different locations. In some cases, less frequent administration may be required. The intensity may vary depending on the half-life of the antagonist in the patient and the desired duration of treatment.
[0077] As described above, the modulator / antibody or pharmaceutical composition of the present invention may be administered in combination with one or more other It may be co-administered with a therapeutic agent.
[0078] The co-administration of two or more drugs can be accomplished in a number of different ways. They may be administered together or in separate compositions as part of a combination therapy. For example, one may be administered before the other, one after the other, or they may be administered simultaneously. good.
[0079] In one embodiment, the interferon-lambda of the present invention is combined with another therapeutically active compound. In one embodiment, the other therapeutically active compound is administered in combination with another antifibrotic treatment. It's medicine.
[0080] Alternatively, the interferon-lambda may be combined with another therapeutically active compound. For example, a patient being treated with interferon-lambda may be given another interferon Interferon (e.g., type I interferon or type II interferon, e.g., interferon The patient may not have been treated with an antiviral agent such as terferon-gamma.
[0081] References JPEG2024156844000003.jpg24149 JPEG2024156844000004.jpg214131 JPEG2024156844000005.jpg220143 JPEG2024156844000006.jpg226143 JPEG2024156844000007.jpg87131 EXAMPLES
[0082] overview The interferon-lambda (IFN-lambda) family of cytokines (IFN-lambda1 (IL- 29), also known as IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B). IFN-λR1 (IL-28R1) and interleukin-10R2 (IL- 10R2) Signal transduction through separate receptor complexes composed of receptor chains do.
[0083] Hydrodynamic Trauma in an Adriamycin-Induced Murine Model of Chronic Kidney Disease (CKD) Transfection in vivo screening of IFN-λ2 and IFN-λ3 Hits were reported as a measure of renal hydroxyproline levels (renal collagen). The IF was determined based on the level of renal fibrosis, which was determined by a 40% reduction. Both IFN-λ2 and IFN-λ3 significantly increased renal function as measured by serum creatinine. This shows that conditional survival (i.e., not reaching end-stage renal disease) is 50% of the patients were treated with saline transfectants at 49 days after adriamycin administration. When IFN-λ2 was transfected, the rate reached 85%, and when IFN-λ3 was transfected, the rate reached 85%. In a surrogate model of CKD with different stimuli, To verify this antifibrotic effect, both IFN-λ1 and IFN-λ3 were administered to patients with chronic kidney disease. Hydrodynamic transfection in a unilateral ureteral obstruction (UUO)-induced renal fibrosis model in rats The two drugs were administered by intravenous injection and both conferred protection against tubulointerstitial fibrosis.
[0084] The anti-fibrotic effect of IL-28R1 ligand was observed in mature, accumulated extracellular matrix ( Several human primary cell in vitro models of fibrosis read out for ECM proteins Recombinant human IFN-λ1, IFN-λ2 and IFN-λ3 have been identified. These are the primary human cell in vitro models of liver fibrosis, lung fibrosis, intestinal fibrosis, skin fibrosis, and kidney fibrosis. In a mouse model, the expression of fibrosis-associated ECM proteins (fibronectin and collagen) was This resulted in the inhibition of the accumulation of hepatic stellate cells, hepatic stellate cell- Hepatocyte co-culture (basement matrix and TGFβ-induced), hepatic stellate cell-epithelial cell co-culture, TGFβ-induced small intestinal fibroblasts, IL-1α-induced dermal fibroblasts, keratinocyte-dermal renal proximal tubule epithelial cell-renal fibroblast co-culture, renal proximal tubule epithelial cell-renal fibroblast co-culture and monoculture, and This has been seen in several models, including small airway epithelial-IPF lung fibroblast co-cultures. In a more complex glomerular organoid model of sclerosis, patients with relapsing nephrotic syndrome The application of plasma from patients with glomerular sclerosis and renal fibrosis has been shown to be effective in treating many glomerular diseases. A decrease in podocyte numbers and atrophy of processes and stalks consistent with the disappearance and disappearance of podocytes. The application of recombinant IFN-λ2 in this model induced both inflammatory and myeloproliferative disorders in this patient. The changes to podocytes caused by plasma from 100 μg / kg of IgG4 were completely prevented.
[0085] IL-28R1 Ligand Screening for Fibrosis Both In Vitro and In Vivo It has been shown to have a strong anti-fibrotic effect in the induction of renal fibrosis. In an in vivo mouse model, and in association with liver, small intestine, skin, kidney and lung organ systems Numerous in vitro human fibrosis models with primary cells have been described. Therefore, this protein has unexpected potential as an antifibrotic agent in multiple types of fibrosis. It has sexuality.
[0086] method Mouse in vivo IL-28A and its role in adriamycin-induced renal fibrosis in chronic kidney disease (CKD) and IL-28B Female Balb / c mice (at least 6 weeks old and weighing more than 24 g) were cultured in a suitable hydrodynamic cDNA in a selectively transfected expression vector (or After 7 days, mice were given adriamycin (doxorubicin) Mice were given 11 mg / kg IP of cyclosporine and monitored for 49 days. Mice were monitored daily for age and health status, and mice that had lost more than 40% of their starting body weight or Mice showing physical signs of renal failure were sacrificed and data were collected at the end of the 49-day study period. At time points, all mice were sacrificed and kidneys and serum were collected for analysis. Proline was assayed using the QuickZyme assay method (QuickZyme Biosciences ces) and serum creatine was measured using a three-enzyme method in μg / m The serum creatinine was measured as creatinine per 100 mg / mL. Renal fibrosis in the saline + adriamycin group ( hydroxyproline) (shown as "saline" on the graph) was used to determine the greatest disease response. This was set to 100% and used for normalization across treatment groups. Treated animals were not administered adriamycin, and each screening experiment was performed The “HGF” group was administered HGF cDNA and HGF was used as an anti-fibrosis positive control. The 5'-hydroxyproline was used as a quality control and a >40% reduction in hydroxyproline was used as a quality control.
[0087] Effects of IL-28 and IL-29 on renal fibrosis induced by unilateral ureteral obstruction in mice DNA constructs for hydrodynamic transfection of mouse IL28B and human IL29 DNA constructs for hydrodynamic transfection were prepared by NheI-XhoI restriction digestion. The DNA used encodes the human IL29 precursor protein (NP_742152.1). A sequence (NM_172140.1) in the pLive vector (Mir5420, Mirus Bio LLC,545 Science Dr.,Madison,WI 5371 1 USA) and subsequent DNA ligation of the homologous ends. The gene encoding mouse IFNL3 (NP_796370) (mRNA reference sequence NM_ The construct was subjected to BamHI-XhoI restriction digestion of both the vector and insert. Cloned into pLive (Mirus) using abbreviation and subsequent ligation. The gene insertion into pLive was verified by DNA sequencing. It is preceded by the sequence CCACC immediately upstream of the ATG that encodes the initiating methionine of the signal sequence. This vector contains a kanamycin resistance gene and an E. coli (Escherichia coli) The vector contains the pUC origin, which allows DNA amplification in coli. , a mouse minimal alginate for transcribing the human IFNL-1 gene flanked on both sides by introns. [This pLive vector is designed to express long-term proteins in the liver. [enabling expression].
[0088] The DNA construct for hydrodynamic transfection was prepared by Limiting amount of plasmid isolation kit (HiSpeed Plasmid Giga EF The plasmid was isolated from an E. coli culture containing this construct using a PCR kit (Qiagen). The DNA was Sanger sequenced to verify the insert.
[0089] Kanefuji et al. and Liu et al. This explains the actor.
[0090] Protein expression by hydrodynamic transfection (HDT) Mice were treated with pLIVE-human IL-29, pLIV in TransIT-EE vehicle. E-Mouse IL-28B or pLIVE SEAP Vector (Mirus Bio Hydrodynamically transfected with 50 μg of either The vector-containing solution was rapidly (<2.5 seconds) injected intravenously in a volume of 2 ml. General anesthesia with isoflurane was induced before hydrodynamic injection and for at least 1 min after injection. was maintained for a period.
[0091] Quantification of mouse IL-28B and human IL-29 from mouse serum Mouse IL-28B was assayed using a commercially available antibody pair (RnD systems, Cat. No. DY1 Quantitative analysis was performed using the Mesoscale Discovery (MSD) quantitative assay (598B). The mouse serum was quantified and diluted 100-fold to place on a linear standard curve. IL-29 antibody set (Cat. No. B21WD) was used. Quantitatively, mouse sera were diluted 100-fold to lie within the linear range.
[0092] Unilateral ureteral obstruction (UUO)-induced renal fibrosis model of chronic kidney disease Male C57BL / 6 mice (Charles Rivers, MA) weighing at least 19 g were cultured. r) were subjected to a unilateral ureteral obstruction (UUO)-induced renal fibrosis model of chronic kidney disease.
[0093] Surgery was performed using isoflurane-induced general anesthesia and under aseptic conditions appropriate for surgical technique. Mice were subjected to laparotomy, followed by ligation of the left ureter using a 3.0 Mersilk ligature. The muscle walls were closed using 5-0 Vicryl in a continuous pattern and 5-0 Vic The skin was closed with subcuticular sutures using Ryl. Appropriate analgesics were administered pre- and postoperatively. Blood samples were taken at appropriate times as detailed in the Results. The mice were restrained using a mouse restrainer provided with a blood sample pipette to ensure accurate measurement. Using a suction cup, the tail vein was examined by the tail prick method. Thirty microliters of blood was taken from the vein. This sample was placed in a 0.2 ml PCR tube (Thermo Fisher Scientific). mo) and centrifuge (20,000 g, 5 min) to remove as much serum as possible. and stored in new PCR tubes at -80°C.
[0094] On day 19 or 21, mice are anesthetized using isoflurane and blood is withdrawn by cardiac puncture. The mice were then killed by cervical dislocation. The left kidney was removed and two quarters were flash frozen in liquid nitrogen and stored at -80°C. The remaining half was placed in 10% neutral buffered formalin, dehydrated in a tissue processor, and prepared for histological analysis. The paraffin blocks were embedded in paraffin for analysis. Thin sections were cut at 4 μm using a microtome. The slides were then dewaxed, hydrated, and attached to a PicroSirius thread. After staining with PSR, the slides were washed in acidified water. The slides were then dehydrated and cleaned. The slides were dried and then covered with a Hamamatsu slide. Scanned using a scanner.
[0095] Import all slide images into Definiens Developer XD 64 Briefly, cortical regions were manually annotated and analyzed using the brightfield module. The medulla was removed from the analysis by using the CT scan. For the markers, a marker threshold level (e.g., PSR staining) was determined. The algorithm runs on a dedicated server to identify markers that exceed a threshold intensity for each individual marker. The marker area was determined and the area of each marker above a threshold intensity was determined as a percentage of the cortical area. did.
[0096] Histological assessment of the level of fibrosis was performed using a fluorouracil dye, preferably picrosirius red, Masson's trichrome dye. A combination of micrographs and hematoxylin and eosin stained thin sections was used to characterize renal fibrosis. The study was conducted by a blinded investigator with expertise in the field of renal disease. A 10-point scale was used, with 1 being always severe fibrosis and 1 being normal. The parameters examined were tubular basement membrane expansion, epithelial cell flattening, brush border integrity, tubular shrinkage, and tubular endothelial cell occlusion. Shrinkage and collapse of the renal tubules, luminal size of the tubules, infiltration of interstitial cells, structure of the glomerular tuft, expansion of the mesangium Large, infiltrating the glomerulus, expanding the glomerular cavity, glomerular basement membrane, and mesangial matrix there were.
[0097] Definiens image analysis and histological evaluation of the images were performed on the treated mice with Adriamycin. The same was also applied to kidney slices.
[0098] Human in vitro extracellular matrix fibrosis assay measurements a) Cell culture All extracellular matrix (ECM) accumulation assays were performed in 384-well black clear-bottom plates. The assay was performed using a 30-well plate (Greiner Cat. No. 781090) and the media, cell number / well, and Incubation times and stimuli varied depending on the primary cell type used.
[0099] Human hepatic stellate cells (HHSteCs) (ScienCell, Cat. No. sc-5300 ) (passage 4) and human intrahepatic bile duct epithelial cells (ScienCell, catalog number sc-5 100) (passage 3) Co-cultures were cultured in epithelial cell medium with nutrient supplements-phenol red. Not included (EpiCM-prf) (ScienCell, catalog number sc-sc-4101 1000 cells / well (1:1 ratio) were seeded in 25uL of 1000-prf. Human astrocytes (ScienCell) were cultured in astrocyte medium (ScienCell) at 100 Human stellate cell and hepatocyte (ScienCell) co-cultures seeded at 0 cells / well , and seeded at 1000 cells / well (1:1 ratio) in mixed culture medium (ScienCell). I sowed it.
[0100] Human small intestinal fibroblasts (ScienCell) were cultured in renal epithelial cell basal medium + 0.5% FCS. and nutritional supplements (ATCC) were seeded at 2000 cells / well.
[0101] Human dermal fibroblasts were grown in fibroblast growth medium, and human keratinocytes were cultured in keratinocyte culture medium. Fibroblast-keratinocytes were grown in keratinocyte medium and seeded at 1500 cells / well. Cnidocyte co-cultures (9:1 ratio) were grown in a 1:1 mixture of medium at 1500 cells / well. The seeds were sown in wells.
[0102] Human renal proximal tubular epithelial cells (RPTEC, Innoprot) and human renal fibroblasts ( HRF, InnoProt), renal epithelial cell basic medium (ATCC) + 0.5% FCS and 2000 cells per well in co-culture with nutritional supplements (ATCC) The seeds were sown at a ratio of 1:1.
[0103] Human small airway epithelial cells (ATCC) were grown in basal growth medium + bronchial epithelial growth kit supplement IPF134 lung fibroblasts (ATCC) were grown in fibroblast growth medium (FGM). The co-cultures were grown at 2000 cells / well (1:1 ratio) in 100% ethanol. ) were sown.
[0104] b) Measurement of cell proliferation After 7 days of incubation at 37 °C and 5% CO2, Pr estoBlue® Cell Viability Reagent (ThermoFi Cell proliferation was assessed using a ELISA kit (Scher Scientific).
[0105] c) Measurement of ECM accumulation Measurement of individual ECM components: immunofluorescence After 7 days of incubation at 37°C in 5% CO2, cells were washed with PBS. and incubated at 37°C for 15 min in 0.25M NH4OH / 25mM Tris (Sigma). The matrix was then dissolved in PBS at 20 μl / well. The cells were washed three times and fixed with 40 μl of 100% methanol at -20°C for 30 min and then resuspended in PBS. After washing three times, anti-fibronectin antibody (eBiosciences), anti-collagen antibody ( I antibody (Millipore), anti-collagen III antibody (Millipore), anti-collagen Anti-collagen IV antibody (eBiosciences) and anti-collagen V antibody (Abcam ) was used for staining. Bio-applications and 2x2 binning (1.10 4 ×1.10 4 Pixels / view A 3-channel protocol was used under a 10× objective lens (new X1 camera) with a 10× field of view. The plates were scanned on an Arrayscan HC reader (Cellomics) using I did.
[0106] Measurement of total ECM components: Flamingo™ staining After washing the immunofluorescence plate three times with Flowfusor water, follow the manufacturer's instructions. The gels were stained using Flamingo™ fluorescent gel stain (BioRad). Cellomics CellHealth" Profiling Bioapplications , and 2×2 binning (1.10 4 ×1.10 4 10x objective lens with 10x pixel / field of view Using a two-channel protocol, the plate was aligned to the Arr Scanned using an ayscan HC reader (Cellomics).
[0107] How to generate 3D human glomerular spheroids Spheroid generation and processing Stably transfected GFP-tagged actin, conditionally immortalized SV40-transfected Dyed podocytes and human thread provided by the University of Bristol Nano-shuttle-PL (CaCl) was added to a T75 flask of human rhabdomeric endothelial cells (HRGEC). Catalog No. 657841) and a nutritional supplement kit (catalog no. 657841) from Lonza. Log number CC4147) and RPMI 1640 medium (10% FCS, 5 mL L -glutamine, and 1XITS (Gibco) and EBM-2 medium. P-transfected podocytes were confirmed by FACS. TrypLE Express (Gibco), and magnetized HRGECs were plated onto a 96-well plate with low-temperature attachment. Place 5,000 cells / well in a Greiner plate (cat. no. 655976). The 96-well plates were seeded with Greiner Spigen cells for 6 hours. Place the roid drive (catalog number 655830) in the culture medium and incubate at 37℃ / 5%CO2 / 10 Spheroids were grown in EBM-2 medium at 0% humidity. The drive was removed. Magnetized GFP podocytes were seeded at 5,000 cells / well. The drive was incubated overnight. Put it back down and use the Holding Drive to feed it every 3 days for 10 days. The spheroids were then incubated with hESC-100 at a final concentration of 15% for 7 days. The mice were treated with FSGS plasma ± IL-28A (10,000 ng / mL) or medium alone.
[0108] Fixation and staining The spheroids were incubated in 10% formalin / 1% Triton X-100 / PBS at 4°C. After 3 x 10 min PBS washes, the spheroids were , 25%, 50%, 75%, and 95% PBS for 30 min each at 4°C. The spheroids were dehydrated in a series of methanol and then left in 100% methanol overnight. After washing with PBS as above, the cells were incubated overnight at 4°C in 3% BSA-containing buffer. Blocked with PBST (0.1% TritonX-100 in PBS) for 4 × 30 min. After washing with PBST, secondary antibody (1:500 / PBST:Alexa GAR-AF64 7 and GAM-AF555) were added to enhance the GFP signal. AF488 was added at 1:200 for 24 h. Spheroids were washed (4 × 30 min). After imaging with a Yokogawa Confocal Quantitation 1 (CQ1) microscope at ×20 magnification, The image was captured.
[0109] Quantification of podocyte cell marker area Maximum intensity projections were imported into Definiens Developer XD 64. The spheroid regions were manually annotated and analyzed using the immunofluorescence module. A threshold level for each marker was determined and an analysis algorithm was run to determine the concentration of each marker. The marker regions that exceeded the threshold intensity for each marker were determined. The area of the spheroids was determined as a percentage of the area of the spheroids.
[0110] result (1) Adriamycin-induced mouse model of chronic kidney disease (CKD) The first member of a hydrodynamically transfected cDNA pair was the mouse Adriamycin Screening for fibrosis-modifying proteins in a mouse IL-1-deficient CKD model 28A(IFNL2) was identified (n=15 mice). , and total kidney hydroxyproline was significantly increased compared to the saline transfection control group. Reduced renal fibrosis measured by phosphorus by 51% (p=0.02) (Figure 1(a) and Figure 1(b)). b)), and renal function was normalized based on serum creatinine levels (p<0.05) (Figure 1 (c)) The antifibrotic effect of IL-28A was examined independently in the same model using IL-28A. Validated in replicate studies transfecting cDNA (n=22 mice per group) IL-28A significantly increased total renal hydroxyproline compared to saline controls. The study reduced renal fibrosis measured by ELISA by 48% (p=0.0004) (Figure 2(a) and Figure 2(b)). (b)) but the loss of renal function returned to normal range as measured by serum creatinine. (vs. 4.8 μg / ml in the untreated saline control group) In the IL-28A group, mean serum creatinine was 1 μg / ml (p<0.0001); mean Treatment group serum creatinine = 0.8 μg / mL) (Figure 2(c)). The measured conditional survival rates ranged from 50% in the saline-treated adriamycin group to 100% in the mice When transfected with IL-28A, the increase was 85% (Figure 2(d)). 49 On day 1, the surviving mice (untreated (n=8), untreated adriamycin animals (n=2) 0), and whole kidneys from IL-28A hydrodynamically transfected animals (n=19) The organs were fixed, embedded in paraffin, sectioned, and stained with Masson's Trichrome (MT) or picron. The slides were stained with either Sirius Red (PSR) or Fluorescent Red (FVR) and scanned with a Hamamatsu slide scanner. Imaged: 1 untreated, 3 untreated adriamycin, and 3 IL-28B treated. Exemplary and representative images of PSR stained kidneys for adriamycin animals are shown in FIG. 5(f). Adriamycin treatment resulted in approximately 50% of glomeruli showing cytotoxicity, mainly in the glomerular basement membrane. However, increased PSR staining in the mesangial matrix also indicated glomerular sclerosis. In the tubulointerstitium, there is consistent expansion of the tubular basement membrane in >70% of the cortex. There are many tubules with large dilations of the tubules leading to a large lumen lacking brush borders. These areas show squamous epithelium with a significant loss of structure. Has infiltration.
[0111] The administration of IL-28A almost completely prevented the signs of glomerulosclerosis and reduced glomerular basement membrane plaque formation. There was little evidence of thickening. Only 2 of 22 animals showed significant signs of epithelial flattening. The remaining animals showed near-normal luminal enlargement in >80% of the cortex. The lesions appeared in the tubular interstitium with little to no effect of the tubular basement membrane.
[0112] Forty-seven mouse kidney samples stained with PSR were analyzed using Definiens software. The areas of PSR staining measured in the three groups were analyzed using high content image analysis. The percentage of SR-stained area was plotted (Figure 5(g)). The mice were then randomly assigned to a randomized controlled trial, with blinded pathological assessment of the extent of fibrosis by two individuals with expertise in renal pathology. A nephrology specialist assessed the fibrosis on a 0 to 10 point scale (0 indicating no fibrosis, 1 indicating no fibrosis). PSR-stained slides were scored using a scoring scale of 0, with 0 indicating the highest degree of fibrosis. Treatment with -28A significantly reduced pathology scores by 47% compared to the untreated group (p<0.0001 ) (Figure 5(h)). A second nephrology expert assessed the pulmonary function on a scale of 1 to 10 (1 being fibrosis, 2 being schizophrenia, 3 being fibrosis, 4 being schizophrenia, and 5 being schizophrenia). 47 MT-stained slides were manually screened using a 10-point scale (10 indicates no disease, 10 indicates best). The IL-28A-treated group showed a significantly lower level of fibrotic remodeling compared to the untreated group. A clear improvement (p<0.0001) was again observed (Figure 5(i)).
[0113] The first member of a hydrodynamically transfected cDNA pair was the mouse Adriamycin Screening for fibrosis-modifying proteins in a mouse IL-1-deficient CKD model 28B(IFNL3) was also identified (n=15 mice per group). Transfected pairs had significantly lower total kidney hyaluronan compared to saline transfection controls. The study reduced renal fibrosis measured by roxyproline by 59% (p=0.00086) (Figure 3 (a and Fig. 3(b)), renal function was normalized based on serum creatinine levels (significant (Figure 3(c)). The antifibrotic effect of IL-28B was independently confirmed in the same model. This was confirmed in a replicate study in which IL-28B cDNA was transfected into mice (n = 10 per group). Renal fibrosis, as measured by total renal hydroxyproline, was significantly greater in saline-treated mice than in control mice. The mean mean mean was 65% lower than that of the control group (p = 0.0000018) (Figure 4(a) and Figure 4 (b)), but renal function remained normal compared with a significant increase in the untreated saline control group. (mean of 3.2 μg / ml in the untreated adriamycin saline control group) In the IL-28B group, the mean serum creatinine was 1.2 μg / ml (p<0.0 5); mean untreated serum creatinine = 0.8 μg / mL) (Figure 4(c)). Survival rates increased from <50% in adriamycin-naive animals to 100% in those treated with IL-28B. The number of mice that survived (untreated (n=4)) increased to 100% of the number of mice that survived (n=4)). 10), untreated adriamycin animals (n=18), and IL-28B hydrodynamic transactivation All kidneys from infected animals (n=22) were fixed, paraffin embedded, and sectioned. Hematoxylin and eosin (H&E) or picrosirius red (PSR) were used. The slides were stained with either of the following and imaged using a Hamamatsu slide scanner. For untreated adriamycin and three IL-28B-treated adriamycin animals An exemplary and representative image of PSR stained kidney is shown in Figure 5(a). Kidneys from untreated mice were Extensive tubular dilatation with marked expansion of the tubular basement membrane, flattening of the tubular epithelium, and loss of the brush border Patients had extensive glomerular sclerosis and tubulointerstitial fibrosis with hypertension and tubular atrophy. Overall, IL28B-treated mice were largely protected from both types of fibrotic remodeling. 50 mouse kidney samples stained with PSR were analyzed using the Definiens software. The areas of PSR staining measured in the three groups were analyzed using high content image analysis. The percentage of the SR stained area was plotted (Figure 5(b)). Colored areas were normalized relative to a 3-fold increase in untreated kidneys (p<0.0001). Fifty mouse kidney slides were analyzed for fibrosis by three individuals with expertise in renal pathology. The clinical pathologists assessed the severity of fibrosis using a 0-4 point scale (0 being no fibrosis, H&E stained slides were scored using a scoring range of 4 indicating minimal fibrosis and 4 indicating the most severe fibrosis. The pathology score was scored. IL-28B treatment significantly reduced the pathology score by 45% ( p<0.01) (Figure 5(c)). Two expert nephrologists scored the patients on a 1–10 scale. A PSR staining analysis was performed on 50 cases using a 10-fold scale (1 indicating no fibrosis and 10 indicating the best fibrosis). The color slides were manually scored. The IL-28B-treated group showed significantly less fibrosis remodeling compared to the untreated group. The results again showed a clear improvement in the ring level (p<0.0001) (Figure 5(d) and Figure 5( e).
[0114] (2) Primary human cell in vitro models of organ fibrosis (2.1) Liver fibrosis Primary human astrocytes grown on plastic self-activate and bind ECM proteins. As measured by the levels of fibronectin, collagen IV, and collagen I & III This ECM accumulation is consistent with the accumulation of recombinant I Treatment of the cultures with L-28A could inhibit this in a dose-dependent manner (Figure 6(a)). Co-culture of human stellate cells and primary human hepatocytes (1:1 ratio) with recombinant human IL-28A Treatment also results in a basement extracellular matrix that can be inhibited in a dose-dependent manner, resulting in fibroblasts. Nectin, collagen IV, and collagen I & III are decreased (Figure 6(b)).
[0115] TGFβ1 stimulation of both stellate cell monocultures and stellate-hepatocyte cocultures increased the ECM Further details on the proteins fibronectin, collagen IV, and collagen I & III. Stellate cell monocultures or stellate-hepatocytes stimulated with TGFβ1 induced an increase in Treatment of the co-cultures with either IL-28A or IL-28B increased the expression of IL-28A or IL-28B. At the highest concentration of B, 10 μg / ml, there was almost complete inhibition of any increase in all ECM proteins. IL-28A inhibited TGFβ1-stimulated hepatic It was more potent than IL-28B across all ECM proteins in the cells (Figure 7(a ) and Figure 7(b)). Images of co-culture ECM stimulated with TGFβ1 in the presence of TGFβ1 treatment alone showed a clear reduction in ECM volume compared to control, which is consistent with the image analysis quantification (Figure 8).
[0116] (2.2) Small intestinal fibrosis Human small intestinal fibroblasts stimulated with TGFβ1 (10 ng / ml) secreted extracellular matrix Induces the production of the proteins fibronectin and collagen I & III. The levels of cytokinin were reduced by 76%, 73%, and 51%, respectively, compared to the control TGFβ1 stimulation. 83% inhibition by IL-28A, IL-28B and IL-29 (10 ng / ml) Collagen I & III significantly inhibited the expression of IL-28A, IL-28B and IL-2 9 (10 ng / ml) inhibited the expression of collagen by 48%, 33%, and 35%, respectively. TGFβ1 stimulation was significantly inhibited only by IL-28A compared to control TGFβ1 stimulation. (37% inhibition at 10 μg / ml) (Figure 9).
[0117] (2.3) Dermal fibrosis Co-cultures of human primary dermal fibroblasts and primary keratinocytes (9:1 ratio) By simply consuming the fibronectin, collagen I & III, and collagen IV were accumulated in significant amounts. Three separate batches of fibroblasts were used in combination with keratinocytes from a single donor. Cultures were treated with either IL-28A or IL-28B. The percentage inhibition of ECM proteins was measured in all three fibroblast batches and the average inhibition was plotted. Both IL-28A and IL-28B inhibited 1-HT1cAb with similar potency (Figure 10). At the highest concentration of 0 μg / ml, it completely inhibited all four matrix proteins. Both IL-28A and IL-28B inhibited collagen IV E at 10–10,000 ng / ml. The dose-dependent inhibition of CM markers was observed. Cell viability was measured using the prestoblue assay. Neither IL-28A nor IL-28B were toxic at any of the concentrations tested. It was shown that this was not the case (Figure 10).
[0118] Dermal fibroblast-keratinocyte co-cultures were cultured at 1250-10000ng / ml IL-29, IL-28A and IL-28B were tested over a narrow concentration range. and fibronectin, collagen I & III and collagen II were significantly increased in comparison to the control co-cultures. A dose-dependent inhibition of collagen IV was observed (Figure 11). IFNL inhibited IFNL-induced cell death by IFNL. ue IL-29, IL-28A or IL-2 was unaffected by treatment with 8B (Figure 11).
[0119] IL-29, IL-28A and Images of untreated dermal co-cultures compared to IL-28B test co-cultures showed that 10ug / ml We confirmed the complete prevention of ECM accumulation as determined by image analysis in the presence of IFNL (Figure 1 2).
[0120] Finally, human dermal fibroblasts were stimulated in monoculture with IL-1α (10 ng / ml). The ECM proteins fibronectin, collagen I & III, and collagen I V. IL-28A or IL-1α stimulated fibroblast monocultures Treatment with 28B resulted in all phenotypes with complete inhibition of the matrix at the highest concentration of 10 μg / ml. showed a strong inhibition of the pro-matrix response of ECM proteins in fibroblasts. In batches, IL-28A was more potent than IL-28B, and one representative example is shown (Figure 13 IL-28A or IL-28B significantly increased cell viability as measured by prestoblue. had no effect on the oxidative stress response (Figure 13).
[0121] (2.4) Renal fibrosis Human primary renal proximal tubule epithelial cells (RPTECs) co-cultured with human primary renal fibroblasts (1 The cells were plated at 2000 cells / well in a 5:1 ratio of fibronectin and collagen I & III produced a highly robust ECM. These co-cultures were then Treatment with IL-29, IL-28A, or IL-28B was performed using three different protocols: I understood.
[0122] First, IL-29, IL-28A, and IL-28B were added to the kidney cocultures on day 0. The cultures were incubated for 7 days. All three cytokines were The accumulation of pronectin and collagen I & III was strongly inhibited in a dose-dependent manner (Figure 14( a) IL-29 showed the most potent effect, with no significant difference between IL-28A and IL-28B. Cell viability was not impaired by cytokine treatment (Figure 14). (a)).
[0123] Next, on day 0, IL-29, IL-28A, and IL-28B were added to RPTEC cells. After 24 hours, fibroblasts were added and the culture was continued for a total of 7 days, after which E IL-29, IL-28A and IL-28B were all expressed in fibronectin-derived IL-10 cells. The accumulation of nectin and collagen I & III was again inhibited in a dose-dependent manner (Figure 14(b)). The magnitude of inhibition of ECM proteins in the presence of IFNL was not observed in both cells at the same time. RPTECs were then subcultured for 24 hours before ECM co-culture induction was initiated by the addition of fibroblasts. The effect was greater when itcaine was added (compare Fig. 14(a) and Fig. 14(b)). .
[0124] Finally, on day 0, fibroblasts were loaded with IL-29, IL-28 and IL-28B. After 24 hours, RPTECs were added and co-culture was continued for a total of 7 days to induce fibronectin and The addition of IFNL to fibroblasts first also reduced the EC The results showed a significant inhibition of M protein (Figure 14(c)), whereas the co-cultures at day 0 Both the addition of cytokines to RPTECs 24 h prior to fibroblasts and the addition of cytokines to RPTECs 24 h prior to fibroblasts In comparison, the potency of IL-29, IL-28A and IL-28B was reduced. Inhibition of ECM signaling in co-cultures of both epithelial and fibroblastic cell types Pointing out IL-28R1-mediated signaling responses in RPTECs that mediate an antifibrotic phenotype We clearly demonstrated the differential effects of the order of addition of IFNL to different cell types versus simultaneous addition. To demonstrate this, data for IL-28A, IL-28B, and IL-29 were collected for each individual IL- Showing the relative effect of different addition protocols on the level of inhibition for the 28R1 ligand Regarding fibronectin (Figure 15(a)) and collagen I & III (Figure 15 (b)) Replotted. At the lower concentration, the cells and cytoplasmic markers were significantly increased compared to those added to RPTECs first (before fibroblasts). The differences between the simultaneous addition of tocainine reached statistical significance and these values were plotted show.
[0125] Cell viability was measured by presto blue, which indicates that the co-cultures The initial addition of cytokines to RPTECs or fibroblasts prior to cell proliferation was not impaired. (Figures 14(a), 14(b), and 14(c)).
[0126] IL-28A, IL-28B and IL-29 test co-cultures compared to untreated co-cultures Representative images (one of 16 total fields per treatment) show IL-29, IL Dose-dependent effects of IL-28A and IL-28B and the presence of 1000ng / ml IL-29 The nearly complete inhibition observed below (Figure 16) is shown, supporting the image analysis data. .
[0127] Renal proximal tubule epithelial cells (RPTECs) in monoculture express low levels of plastid In Figure 22, fibronectin accumulates basal ECM proteins by growing on the fibronectin matrix. As shown for collagen I, collagen IV, and collagen I and III, low levels of ECM , but can still be inhibited in the presence of very low concentrations of IL-29.
[0128] (2.5) Pulmonary fibrosis Human primary alveoli in co-culture with pulmonary fibroblasts isolated from patients with idiopathic pulmonary fibrosis (IPF) Lung epithelial cells (2000 cells / well at a 1:1 ratio) produced robust total ECM after 7 days in culture (measured by Flamingo staining) and the ECM marker fibronectin, The results were positive for collagen I & III and collagen IV. -28B had no significant effect on fibronectin levels. -28B inhibits collagen I & III, collagen IV, and collagen VI at a maximum concentration of 10 μg / ml. The effect of IL-28A was not significantly different from that of IL-28A. Neither IL-28A nor IL-28B significantly increased the IL-28 expression level on day 7. There was no change in cell viability (Figure 17).
[0129] (3) Primary human cell models of organ fibrosis (3.1) Liver fibrosis Co-culture of primary human stellate cells and primary human intrahepatic bile duct epithelial cells (1:1 ratio) was performed using recombinant human Basal extracellular matrix protein (ECP) levels can also be inhibited in a dose-dependent manner by treatment with IL-28A and IL-29. Provides matrix, fibronectin, collagen IV, and collagen I & II I decreases (Figure 19).
[0130] (3.2) 3D glomerular spheroid model Temperature-conditioned human podocyte outer cores that can be maintained in stable culture for up to 3 weeks We constructed glomerular spheroids from the inner cores of magnetized human primary glomerular endothelial cells. Glomerular spherification using 15% recurrent plasma from patients with focal segmental glomerulosclerosis (FSGS) Treatment with IL-28A inhibited the expression of GFP-labeled podocytes from the outer nucleus, which could be protected in the presence of IL-28A. Plasma from healthy volunteers had no effect on podocytes. Quantification of color fluorescent podocyte marker area significantly increased FSGS recurrence with IL-28A treatment There was a significant decrease in the presence of plasma (Figures 20(a), 20(b) and 20(c)). The clinical progression of FSGS is characterized by the disappearance and loss of podocytes. S. Reproduces the effects of circulating factors in plasma on podocytes and is associated with nephrotic syndrome. and suggest the clinical translational potential of IL-28 therapy to prevent glomerulosclerosis.
[0131] (4) Murine unilateral ureteral obstruction (UUO) model of renal fibrosis (4.1) Mouse IL28 delivered by hydrodynamic transfection (HDT) B The UUO kidneys of animals administered the control SEAP vector by HDT were On day 1, the model showed typical tubulointerstitial fibrosis in the cortex, with extensive tubular basement membrane involvement. Extensive enlargement, strong collagen staining due to basement membrane, especially strong staining within the medulla, and epithelial cell volume The renal function was characterized by extensive loss of tubules, tubular atrophy, loss of proximal tubule brush borders, and extensive tubulointerstitial infiltrates. Less than 15% of the tubules had a nearly normal structure. Changes to the glomeruli were minimal. However, the medulla was virtually destroyed and missing (Figure 21(a)).
[0132] Animals undergoing HDT with murine IL-28B 1 day before and 7 days after UUO Both UUO kidneys showed protection from cortical tubulointerstitial fibrosis 21 days after surgery. (Figure 21(a)). The enlargement of the tubule base and collagen staining were significantly higher than those of the control vector. Compared with UUO mice treated with IL-28B, both groups were treated with murine IL-28B via HDT. Both IL28B groups preserved tubular structure. However, the incidence of epithelial flattening and atrophy was less. In these cases, 30-40% of the tubules showed almost normal structure and subsequent treatment The incidence of interstitial infiltration was slightly lower (20-30%) than in the control vector group. In both IL-28 groups, the medullary structure was significantly increased. Overall, HDT did not have a significant effect on the early and late protection of IL28B. Delivery of both mediates significant protection from UUO-induced fibrotic remodeling in the renal cortex. did.
[0133] Collagen thin sections stained with picrosirius red (PSR) are shown in definiens images. Analysis algorithms were used to quantify and compare total Either collagen regions (Figure 21(b)) or high strength collagen regions (Figure 21(c)) When plotted as IL-2 delivered on either day -1 or day 7, This shows a statistically significant protective effect of 8B on the visual appearance of stained sections as described above. This is consistent with the histological evaluation by
[0134] Mouse IL28B protein achieved 21 days after HDT in a mouse UUO model Serum levels of creatine were measured by ELISA and ranged from 43 to 485 ng / ml across all groups. Mouse IL28B protein could not be measured in control SEAP HDT mice. Therefore, this level is within the lower limit of quantification (LLQ) of the assay used, 4 ng / mL. It was less than l.
[0135] (4.2) Human IL-29 delivered by hydrodynamic transfection (HDT) Human IL-29 delivered by HDT was significantly higher than that of the SEAP control plasmid-treated group. In comparison, day 0 (24 hours after transfection) and day 19 after the model was terminated Both days show significant protein expression in all mice (Figure 23(a)). Human IL-29 was not detected in the serum of transfected or SEAP control mice. could not be detected.
[0136] Untreated 19-day UUO showed histological changes typical of this model. There is widespread destruction and loss of the medulla. The cortex is enriched with increased picrosirius red ( The tubular basement membrane was associated with significant interstitial collagen accumulation as shown by PSR staining. There is also a marked infiltration of cells into the interstitium throughout the cortex. The epithelial structure is severely damaged. Most of the epithelial cells, including a few tubules with dilated lumens, In particular, over 80% of the tubules appear to have extensive The lumen of the tubule undergoes atrophy and in many cases collapses completely. Due to the nature of the nephron, epithelial cells are difficult to distinguish in most cases. It is clearly detached from the tubular basement membrane and lies within what would likely be the lumen.
[0137] 19-day UUO kidneys treated from the time of UUO with IL-29 showed The appearance is dramatically different from that of the control, with the structure clearly preserved. Damaged but still present, with more damage compared to untreated UUO in 75% of animals In this cortex, the main observation at lower levels of magnification is the SEAP Compared to UUO, there are many tubules with dilated tubule lumens. However, This is consistent with the extremely flattened epithelial cells and the expansion of the tubular basement membrane in untreated UUO. If this is relevant, IL-29 treatment may help preserve the volume of these epithelial cells. The tubular basement membrane was minimally expanded, and the tubular architecture was significantly preserved, with no atrophy or There is little or no evidence of tubular collapse. Significantly lower levels of interstitial collagen. Overall, the application of IL-29 improved the progression of UUO. It significantly reduced tubulointerstitial fibrosis caused by urinary incontinence, and reduced interstitial collagen and 23(b) with dramatic preservation of tubular architecture as shown in the representative images in Fig. 23(c) and Fig. 23(d).
[0138] All picrosirius red (PSR)-stained collagen sections were analyzed using the definiens fraction. Image analysis algorithms were used to quantitate and compare with control SEAP plasmid-treated mice. When plotted as total collagen stained area compared to human IL-1 delivered on day -1 The results show a statistically significant protective effect of -29 (Figure 23(c)). This is consistent with visual histological evaluation of stained thin sections.
Claims
[Claim 1] The invention as depicted in the drawings.
